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Abstract
Bovine adenovirus type 3 (BAV3) is a medium size DNA virus that
causes respiratory and gastrointestinal disorders in cattle. The viral
genome consists of a 35,000 base pair, linear, double-stranded DNA
molecule with inverted terminal repeats and a 55 kilodalton protein
covalently linked to each of the 5' ends. In this study, the viral genome
was cloned in the form of subgenomic restriction fragments. Five EcoRI
internal fragments spanning 3.4 to 89.0 % and two X b a I internal
fragments spanning 35.7 to 82.9 % of the viral genome were cloned into
the EcoRI and Xbal sites of the bacterial vector pUC19. To generate
overlap between cloned fragments, ten Hi n dIll internal fragments
spanning 3.9 to 84.9 and 85.5 to 96% and two BAV3 BamHI internal
fragments spanning 59.8 to 84.9% of the viral genome were cloned into
the HindllI and BamHI sites of pUC19. The HindlII cloning strategy
also resulted in six recombinant plasmids carrying two or more Hi ndII I
fragments. These fragments provided valuable information on the
linear orientation of the cloned fragments within the viral genome.
Cloning of the terminal fragments required the removal of the residual
peptides that remain attached to the 5' ends of the genome. This was
accomplished by alkaline hydrolysis of the DNA-peptide bond. BamH I
restriction fragments of the peptide-free DNA were cloned into pUC19
and resulted in two plasmids carrying the BAV3 Bam HI terminal
fragments spanning 0 to 53.9% and 84.9 to 100% of the viral genome.
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Nucleotide sequence of the vector-insert junctions showed the presence
of the terminal repeats unique to adenoviruses, thereby confirming the
identity of these fragments. All of the constructed plasmids were
mapped with the restriction endonucleases BamHI, ClaI, EcoRI, HindIII,
KpnI, NotI, NspV, PstI, PvuI, Sail, XbaI and Xhol. The linear
arrangement of all of the cloned fragments was determined by
overlapping the restriction maps of the fragments. The recognition sites
for the twelve restriction endonucleases were translated to the linear
form to yield a detailed restriction map of the BAV3 genome.
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Introduction
Adenoviruses (Ads) were first isolated in 1953 during attempts to
culture tonsilar and adenoidal tissue surgically removed from children
(Rowe et al., 1953). Soon after they were first isolated, Ads were
implicated as a causative agent of primary atypical pneumonia and
acute respiratory disease in military recruits (Hilleman and Werner,
1954). In 1956 the name "adenoviruses" was coined (Enders et al.,
1956); prior to that Ads were known as Adenoid degeneration (AD),
Acute Respiratory Disease (ARD) and Adenoid-pharyngeal conjunctival
(APe) agents.
There are well over 80 serotypes of Ads described to date, 48 of
which are of human origin and the remainder infect various other
species including bovine, equine, canine, ovine, porcine, simian, and
avian. Although most Ad infections are subclinical, 30% of the Ads
serotypes cause a number of clinical respiratory and gastrointestinal
disorders in both humans and animals. Most individuals would have
encountered at least one Ad serotype by 15 years of age. Ads are
responsible for approximately 5% of respiratory diseases, 10% of
pneumonia and 7 to 17% of gastroenteritis cases in children (reviewed
by Roos, 1989; Horwitz, 1990) Furthermore, Ad infections can cause
hepatitis, acute hemorrhagic cystitis, encephalitis, and ocular infections
that include conjunctivitis and keratoconjunctivitis (Bennett et al., 1957;
Dawson et al., 1975; reviewed by Roos, 1989; Horwitz, 1990). Table 1
summarizes some of the diseases caused by various Ads.
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Adenovirus type 12 (AdI2) was the first human pathogen
associated with the production of tumors in rodents (Trentin et al.,
1962). Soon after, bovine adenovirus type 3 (BAV3) was also shown to
cause oncogenic transformation in hamsters and mouse cell lines
(Darbyshire et al., 1966). This finding resulted in pioneering research
that made Ads a well understood model system for many eukaryotic
molecular processes. Splicing and posttranslational processing of mRNA
were first observed in Ad systems. Furthermore, techniques such as
mRNA mapping of the genomic location of genes, S1 nuclease protection
assay and in vitro replication systems were first developed in studies of
Ads (Chow et al., 1977; Berk and Sharp, 1977; Challberg and Kelly, 1979;
Ricciardi et al., 1979). Today, there is a vast amount of information on
human adenoviruses, particularly serotypes 2, 5 and 12, and little is
known about members of the other groups especially those of bovine
orIgIn. Consequently, most of the information presented in the
following section comes from studies involving human Ads.
Hybridization of BAV3 to Ad2 DNA suggested a high degree of
similarity between these viruses in terms of gene structure and
organization. To better understand genomic organization, gene
expression and oncogenic properties of BAV3, it is essential to construct
a detailed restriction map of the viral genome. The objectives of this
study were to clone the BAV3 genome and construct a detailed
restriction endonuclease map of the viral DNA.
1 0
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~ Table 1. Diseases associated with Adenoviral infection.
Virus
Ad 1, 2, 3, 5, 6, 7
Ad 3, 7,14
Ad 3,4, 7, 14, 21
Ad 1,2,3,7
Ad 4, 7
Ad 8, 11, 19, 37
Ad5
Ad 11,21
Ad 40, 41
Ad 1,2,5
Ad 34,35
BAV 1,2,3
BAV4
BAV 5, 7
BAV6, 8
BAV7
CAY 1
CAV2
PAY 1,2,3
PAV4
Disease
Acute febrial pharyngitis
Pharyngoconjunctival fever
Acute respiratory disease
Pneumonia
Pneumonia
Epidemic Keratoconjunctivitis
Pertussis-like syndrome }
Acute hemorrhagic cystitis
Gastroenteritis
Hepatitis
Persistence of virius
in urinary tract
Pneumonia, enteritis
Fibrinous enteritis,
Pneumoenteritis
Weak calf syndrome
Mild respiratory illness,
Catarrhal conjunctivitis
Pneumoenteritis
Acute Hepatitis
Laryngotrachetis
Enteritis
Pneumonia, Encephalitis
Comments
5% of disease cases
Military (fatigue / crowding)
Infants and young children.
Ad 40, 41 cause 7 -17% of
intestinal infections.
Liver transplant.
AIDS, immunosuppressed.
Weight lose and poor dairy
production.
Can be fatal.
Chapter 1: Literature Review
1.1 Classification:
Ads belong to the family Adenoviridae, which is divided into two
genera: Mastadenovirus and Aviadenovirus. The Aviadenovirus genus
includes Ads that infect avian hosts whereas all other Ads are grouped
in the Mastadenovirus genus (figure 1). Bovine adenoviruses are
further divided into two subgroups: subgroup I that includes serotypes
1, 2, 3, and 9 and subgroup II that includes serotypes 4 to 8 (Bartha,
1969; figure 1). The difference between the two genera (aside from the
host) is the group-specific antigen that is present only in the
Mastadenovirus. This classification scheme is based on the natural host
species, hemagglutination of red blood cells, serum neutralization,
complement fixation, oncogenicity, DNA base composition and homology,
and restriction endonuclease profiles of the viral genomes (Pina and
Green, 1965; Garon et al., 1973; Adair and McFerran, 1976; Adrian et al.,
1986; Adam et al., 1988; Adrian et al., 1990).
1.2 Particle Structure:
Ads are nonenveloped, regular, icosahedral-shaped particles
composed of 13% DNA and 87% protein (Horne et al., 1959; Green and
Pina, 1963; figure 2A). The protein capsid is comprised of 252
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Figure 1. Schematic representation of the classification of
adenoviruses.
capsomers that surround a DNA containing core (Horne et al., 1959).
The icosahedral structure is 65 to 80 nrn in diameter with 20 triangular
surfaces and 12 vertices. 240 of the capsomers are called hexons (each
surrounded by six neighbors) and the remaining 12 are called pentons
or penton bases (each surrounded by five neighbors). Figure 2B
outlines the position and the association of the viral peptides relative to
each other and to the genome.
Hexon capsomers are trirners of viral polypeptide II (120
KiloDalton, KDa), held together by non-covalent interactions. Each of the
hexon subunits is associated with six neighboring hexons through the
minor viral polypeptide IX (12 KDa) (Everitt et al., 1975; Ghosh-
Choudhury et al., 1986). The triangular surfaces of the icosahedron are
made up of nine hexon subunits (Prage et al., 1970) associated with
viral polypeptides VI (24 KDa) and VIII (13 KDa).
Through experiments involving iodination (of intact and disrupted
virions), reversible chemical cross-linking, and immunoprecipitation of
the virion with antisera raised against purified viral polypeptides,
Everitt and co-workers (1975) determined that the polypeptides V
(48.5 KDa), VI, VII (18.5 KDa) and VIII are in the core of the virion.
Polypeptides V and VII are associated with the DNA molecule, whereas,
VI and VIII are associated with the internal surface of the hexan
(reviewed by Horwitz, 1990). Penton bases (occupying the vertices) are
composed of 5 viral polypeptide III (85 KDa) monomers, non-covalently
attached to protein spikes that project outward. Ads have one fiber per
penton base with the exception of avian Ads (which have two fibers
projecting out of each penton) and human Ad40 and 41 (which have
two types of fibers expressed per virion) (Gelderblom and Maichle-
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Figure 2: Schematic diagram of the adenovirus icosahedron (A) and
cross section of an adenovirus particle (B). The cross section
shows the position of the viral peptides relative to each other
and genome (A, from Luria et at., 1978; B,from Persson and
Philipson, 1982).
Lauppe, 1982; Kidd et al., 1993). The spike (or fiber) is a trimer of viral
polypeptide IV (62 KDa) that attaches to the penton base through its
conserved amino terminus and has a knob-like structure containing the
carboxy terminus furthest from the capsid (reviewed by Flint, 1981;
Herrison, 1990). BAV3 shares these same structural characteristics
with other adenoviruses (Niiyama et al., 1975).
1.3 Genome Structure:
Ads possess a single copy of a linear double-stranded DNA
genome. The viral DNA ranges in SIze from 30,000 to 36,000 base pairs
(bp) in length and has a 55 KDa protein covalently attached through a
serine-phosphodiester bond to the 5' end of each of the viral DNA
strands (Green et al., 1967; Robinson et al., 1973; Rekosh et al., 1977;
Desiderio and Kelly, 1981). The viral DNA also contains inverted
terminal repeats (ITR) of approximately 100 to 140 bp in length
depending on the serotype (Garon et al., 1972; Haj-Ahmad and Graham,
1986). Moreover, the genome is composed of 48% to 61 % GC depending
on the serotype (Panigraphy et al., 1977).
BAV3 genome is 35,000 bp in length and has 190 bp ITR
(Shinagawa et al., 1987; Elgadi and Haj-Ahmad, 1992). Within the core,
viral DNA is non-covalently associated with viral basic proteins V (48.5
KDa) and VII (18.5 KDa) to form a compact supercoiled structure with
twelve intertwined domains (Wong and Hsu, 1989; Banerjee and
Spector, 1992; figure 2B). By convention., the viral genome has been
divided into 100 map units, with the a map unit located at the left end
and the 100 map unit located at the right end of the genome. Both of
the Ad DNA strands are coding strands, where the right strand (r) IS
transcribed to the right and the left strand (1) is transcribed
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Figure 3:' Schematic representation of the adenovirus type 2 genome
showing the location of the transcription units. Arrows indicate
the exons of the various transcripts. Polypeptides translated from
each transcription unit are shown above or belo\v the unit (from
Tollefson et al., 1992)
to the left (reviewed by Horwitz, 1990). Figure 3 shows a schematic
representation of the adenovirus genome.
1.4 Early Viral Gene Products and their Function:
There are six early viral transcription units located on both the r-
and I-strands of the DNA genome (figure 3). The r-strand contains the
E1a, Elb and E3 units whereas the I-strand contains the E4, E2a and E2b
units. The locations of these units within the genome have been
determined by a number of techniques that include electron
microscopy, S1 nuclease protection assays and viral mutant constructs
(Berk and Sharp, 1977; Ross et al., 1980; reviewed by Horwitz, 1990).
The Ad productive cycle is divided into early and late phases, with the
late phase commencing with the onset of viral DNA replication.
All viral mRNA transcripts are capped and polyadenylated. With
the exception of viral associated RNA genes (VA RNA) which are
transcribed by cellular RNA polymerase III (reviewed by Mathews and
Shenk, 1991), all other viral genes are transcribed by cellular RNA
polymerase II. Each of the early transcription units produces a number
of mRNAs by alternative splicing of a primary transcript.
1.4.1 Early Region 1:
Early region 1 (El) IS located between 1.3 and 11.2 map units
(mu) on the r-strand of the viral genome (figures 3 and 4) . This region
is transcribed into the first mRNAs detected in Ad infected cells. There
are two transcription units, Ela and El b, within the El region (figure
4A). Ela and El b or activated ras, a cellular oncogene, are required for
full transformation of cells in culture (Graham et al., 1974; 1977;
Mckinnon et al., 1982; Jones and Shenk, 1979b), whereas, the Ela alone
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is required for immortalization of primary cell cultures (Ruley, 1983).
The transforming region of BAV3 DNA is also located at the extreme left
end (0 to 11.9%) of the viral genome (Igarashi et al., 1978; Niiyarna et
al., 1981).
E1a is located between 1.3 and 4.S mu (figure 3 and 4). This
region is transcribed into at least S mRNAs (13S, 12S, lIS, IDS and 9S)
that share the cap and poly(A) sites and are generated by alternative
splicing of a primary transcript. The 9S mRNA is transcribed in the late
phase, whereas, the l2S and 13S mRNAs are transcribed in both the
early and the late phases of the infection. The functions of the 9S, IDS
and lIS mRNAs and their polypeptide products are not yet understood.
In AdS, the 13S and 12S mRNAs are translated into 51 KDa (289 amino
acids) and 48 KDa (243 amino acids) polypeptides, respectively (figure
4A andB). Both polypeptides share the same sequence except for a 46
amino acid stretch which is unique to the 51 KDa polypeptide. This
region, conserved between different serotypes, is called the conserved
region 3 (CRIll; figure 4B), and has been found to be responsible for
transactivating other early viral genes as well as some cellular genes
(Svensson and Akujarvi, 1984; Cogan et al., 1992; Weintraub and Dean,
1992). The other two conserved regions (CRI and CRII, figure 4B),
present in both polypeptides, are responsible for transformation and
repression of transcription functions of the E1a unit (Cogan et al., 1992).
In addition to the three conserved regions, the N-termini of the E1a
polypeptides have also been shown to be involved in the regulation of
gene expression and transformation functions (Gedrich et al., 1992;
Weintraub and Dean, 1992). There is an increasing body of evidence
that the 12S Ela protein products are involved in the transactivation of
some viral and cellular genes, such as the viral El a and E2 genes,
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Figure 4: Schematic representation of the El region transcripts and
protein products (A). Panel B shows the E1A 12S and 13S
transcripts and the conserved regions 1(1), II (2), III (3) and the
N-terminus (n) (A, from White and Cipriani, 1989; B, from Cogan
et al., 1992)
cellular heat shock protein (hsp70), and proliferating cell nuclear
antigen (PCNA) (Cogan et al., 1992; Kraus et al., 1992).
The El b transcription unit extends from 4.6 to 11.2 mu on the r-
strand of the Ad genome (figure 4A). A 22S and a 13S mRNA are
transcribed from two different overlapping reading frames within the
El b region. The 225 mRNA is translated into a 19 KDa and 55 KDa
proteins from two different start sites (two different reading frames)
whereas the 13S mRNA is translated into a 19 KDa protein (Bos et al.,
1981). In an Ad infected cell, the 19 KDa protein associates specifically
with and disrupts the organization of the intermediate filaments and
the nuclear lamina of the cell (White and Cipriani, 1989). These
interactions are thought to produce the effect of Elb 19 KDa protein in
preserving the nuclear DNA integrity and cytoplasm architecture, the
destruction of which is induced by the Ela gene products during
productive infection (White et al., 1991; White et al., 1992). Infection of
baby rat kidney cells (KB) with Ad12 mutants in the 19 KDa
polypeptide results in degradation of the infected cell and viral DNAs
(deg phenotype) as well as enhanced cytopathic effects (cyt phenotype)
(Zhang et al., 1992). This may be the result of the inability of the 19
KDa protein to preserve the structural component of infected cells. The
Elb 19 KDa polypeptide was shown recently to protect Ad infected cells
against lysis by tumor necrosis factor (TNF) that is produced in response
to viral infection (Gooding et al., 1991a; White et al., 1992). Based on
these findings, White and colleagues (1992) suggested that the 19 KDa
protein may in fact exert its role in transformation by inhibiting cell
death induced by Ela or TNF, thus allowing the Ela to complete the
transformation of nonpermissive cells. In addition to its role in
preventing infected cell lysis, the 19 KDa protein plays a role in the
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activation of viral Ela, Elb, E2, E3 and E4 genes and cellular hsp70
(Herrmann et al., 1987; Komuc et al., 1990).
The 55 KDa polypeptide product of the Elb region is required,
along with the Ela products, to produce full transformation of cells in
culture. In fact, the overexpression of this polypeptide in the absence
of the other Ad12 oncogene, E1b 19 KDa protein, is sufficient to
transform KB cells (Zhang et al., 1992). This protein has been found to
associate with p53, a cellular protein involved in cell cycle regulation,
which is predicted to be an antioncogene similar to the retinoblastoma
(Rb) oncogene repressor protein (Lavery and Chen-Kiang, 1990).
Therefore, the ability of the 55 KDa protein to augment the E1a products
in transforming cells may occur through this association which would
inhibit the p53 from performing its antioncogenic functions.
The 55 KDa product of Elb is also involved in the regulation of
host-cell RNA metabolism. The complex formed between the 55 KDa
and the E4 34 KDa proteins is thought to interact directly with cellular
factors required for transport of cellular mRNA to the cytoplasm. It was
suggested that this interaction prevents cellular mRNA from
accumulating in the cytoplasm. It has recently been demonstrated that
the 55-34 KDa complex is localized in the periphery of the nuclear
inclusions where the viral DNA is transcribed (Ornelles and Shenk,
1991 ). Moreover, nuclear factors (Sm antigen) and the matrix-
associated antigen (PI1), which are involved in the translocation of
mRNA across the nuclear membrane, are also localized in the same area
as the 55-34 KDa complex suggesting the entrapment of these factors by
the viral protein complex (Ornelles and Shenk, 1991). Although it has
been suggested that the 20 KDa polypeptide product of Elb may be
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involved in stabilizing the pIX transcript, its function IS still unclear
(Babiss and Vales, 1991).
1.4.2 Early Region 2:
The E2 transcription unit (composed of E2a and E2b subunits) is
located between 75 and 11 mu on the I-strand (figure 3). The E2a
encodes a 72 KDa DNA-binding protein (DBP), a basic protein that is
essential for viral DNA replication (Ikeda, et al., 1981). DBP protects the
displaced single-stranded parental DNA molecule from nuclease activity
and enhances the formation of initiation of replication complex at the
origin of replication site (Tsuji et al., 1991). In addition, the DBP plays
an important role in the regulation of viral gene expression and
stabilization of viral mRNAs (Chang and Shenk, 1990; Nevins, 1987).
The E2b unit encodes an 80 KDa preterminal protein and 140 KDa DNA
polymerase, both of which are essential for DNA replication. The
function of these proteins will be discussed in detail in the section
entitled "Viral DNA replication".
1.4.3 Early Region 3:
In human Ads, the E3 regIon is located between 76.6 to 86.2 mu
on the r-strand of the genome (embedded in the major late
transcription unit; figure 3). At least nine major overlapping mRNAs
with different splice patterns and two different poly(A) sites (E3A and
E3B) are expressed from the E3 promoter (Brady and Wold, 1987; Wold
and Gooding, 1991; Tollefson et al., 1992; figure 5). The E3 encodes a 19
KDa glycoprotein (gpI9) (Wold et al., 1985) that binds to the major
histocompatability complex Class I (MHC-I) molecules preventing their
transport to infected cell surfaces (Burgert and Kvist, 1985; Andersson,
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et al., 1985; Ginsberg et. al., 1989). Ad mutants in the gp19 gene
showed a marked decrease in their ability to reduce surface expression
of the MHC-I and increased pathogenic effects (increase in the
lymphocyte and macrophage/monocyte inflammatory response) in
cotton rats (Ginsberg et. al., 1989). Recent evidence has suggested that
the increased sensitivity of cells infected with E3 mutant to cytolysis by
T-cells is due to over expression of E1a proteins rather than changes in
MHC-I function or expression (Zhang et al., 1991). Therefore, by
regulating El a expre~sion and the MHC-I cell surface expression,
perhaps the E3 gp19 helps to protect infected cells against cytolysis by
components of the host immune system (B urgert and Kvist, 1985;
Andersson, et al., 1985; Ginsberg et. al., 1989).
Two of the E3 products, the 10.4 KDa and 14.5 KDa polypeptides
(figure 5), form a complex resulting in the internalization and
degradation of epidermal growth factor receptor (Tollefson et al., 1991).
This is thought to mimic the effect of epidermal growth factor in
stimulating host-cell DNA synthesis and cell division, making the host
cells efficient virus-producing factories (Tollefson et al., 1990a, 1990b;
Tollefson et al., 1991; Wold and Gooding, 1991). The site of action of
these proteins is the cytoplasmic membrane. Both the 10.4 KDa and
14.5 KDa proteins are anchored In the membrane such that their C-
terminal is in the cytoplasm and the N-terminal is in the lumin (Krajcsi
et al., 1992a; Krajcsi et al., 1992b).
The 14.7 KDa protein, product of E3 (figure 5), is sufficient in
protecting Ad-infected cells against lysis by TNF (Gooding et al., 1988).
Transfection of mouse C3HA cells with the 14.7 KDa gene, under the
control of a mouse promoter, results in a decrease in sensitivity to TNF
in a 14.7 KDa expression dose-dependent manner. The decreased
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Figure 5: Schematic representation of the E3 transcripts. The solid
arrows indicate exons and the dashed lines indicate introns. The
abundance of each of the transcripts at early stages of infection IS
indicated by the thickness of the arrows. The hatched and
stippled boxes indicate the polypeptide products of the transcripts
(from Tollefson et al., 1992).
sensitivity to TNF is not due to a reduced TNF receptor nor does the
14.7 interfere with TNF signal transduction (Horton et al., 1991). In the
absence of the 14.7 KDa protein, however, the 10.4 and 14.5 KDa
proteins were shown to protect mouse cells against TNF (Gooding et al.,
1991b)
The E3 transcription unit expresses at least 5 additional mRNA
species encoding 12.5 KDa, 6.7 KDa, 3.6 KDa, 7.5 KDa and 11.6 KDa
proteins (figure 5). The functions of these mRNAs and their products
are not yet known. Since both the 6.7 KDa and the gp19 polypeptides
are translated from the same bicistronic mRNAs (figure 5), it has been
suggested that the 6.7 KDa protein may be functionally related to or act
in concert with the gp 19 (Wilson-Rawls et al., 1990). The 11.6 KDa
protein is a nuclear membrane glycoprotein encoded by two
overlapping mRNAs (Wold et al., 1984; Scaria et al., 1992). This protein
was recently found to be expressed at low levels during the early stages
and 400 times greater levels during the late stages of an infection
(Tollefson et al., 1992). The late stage 11.6 KDa mRNAs share the same
coding sequence and middle exon with the early stage 11.6 KDa mRNAs
(d and e, figure 5), but were spliced at the 5' splice site to the major late
tripartite leader sequence which is part of the major late transcription
unit. This suggests that these mRNAs may have cis- or trans-acting
sequences that might suppress the splicing to the tripartite leader early
and enhance the splicing late in the infection (Tollefson et al., 1992).
The existence of a 12.5 KDa protein, of an unknown function, was
predicted by the presence of an ORF that could encode a protein of that
size. Hawkins and Wold (1992) have been able to demonstrate the
actual presence of this protein using antisera raised against synthetic
peptides corresponding to the ORF. This protein was found to be
26
expressed in small amounts both early and late in the infection
(Hawkins and Wold, 1992).
The E3 encoded proteins appear to be responsible for protecting
infected cells against the host immune response. Therefore, it is not
surprising that the entire region can be deleted with no apparent effect
on viral growth in tissue culture (reviewed by Wold and Gooding, 1991).
1.4.4 Early Region 4:
The E4 region is located between 96.8 and 91.3 mu on the I-strand
of the Ad genome (figure 3). There are 7 different ORFs in the E4
region. Four proteins encoded by E4 have been identified, one of which
is the 11 KDa polypeptide encoded by ORF3. This nuclear matrix
associated protein appears to be dispensable for viral growth in tissue
culture (Horwitz, 1990). ORF6 encodes the 34 KDa protein that
associates with the Elb 55 KDa protein to regulate host cell mRNA
metabolism during infection (Ornelles and Shenk, 1991). The 17.5 KDa
protein product of ORF6/7 was found to complex with the cellular
transcription factor (E2F) to stimulate transcription of the E2 region
early in infection (Marton et al., 1990). The 17.5 KDa protein was also
found to activate other viral genes in the absence of Ela gene products
(Marton et al., 1990). Recently, the 14 KDa product of the ORF4 has
been shown to counter balance the ability of E 1a gene products to
activate viral genes through the cyclic AMP (cAMP) responsive element
(CRE, which is a binding site for API and ATF/CREB family of
transactivating factors) (Mullr et al., 1992; Gedrich et al., 1992). In
addition to these functions, the E4 region of Ad9 has been implicated In
the production of mammary tumors in rodents (Javier et al., 1992).
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Ad mutants with large E4 deletions display complex phenotypes
including defects in viral DNA replication, late gene expression and host
macromolecule synthesis shut-off (Hemstron et al., 1991). This suggests
that E4 products play an important role in the viral productive cycle.
1.5 Regulation of Early Gene Expression:
The regulation of viral gene expression is a complicated cascade of
events involving both viral gene products and host-cell factors. The El
gene products were implicated in regulatory control of viral early gene
expression through the use of Ad host range mutants with deletions in
the El region. These mutant viruses could not propagate in HeLa cells
(Harrison et al., 1977); however, they could carry out a reproductive
cycle in 293 cells (Graham et al., 1978) which constitutively express the
El gene products (Graham et al., 1977). These mutant viruses could
grow in 293 and HeLa cells when co-infected with the wild type virus,
indicating that the El region exerts its regulatory effect on other early
genes in trans (Jones and Shenk, 1979a, b; Berk et al., 1979). The
transactivation function of El has been attributed to the 289 amino acid
polypeptide (specifically CRIll) product of the E1a transcription unit
(figure 4B). Recent evidence involving a mutant expressing the 243
amino acid polypeptide but not the 289 amino acid, however, shows
that the 243 amino acid polypeptide is involved in transactivating the
expression of some genes such as the Ela, E2 genes, and hsp70 (Morris
and Mathews, 1991; Kraus et al., 1992; Weintraub and Dean, 1992). The
observation that HeLa cells treated with cycloheximide (an inhibitor of
protein synthesis) and infected with Ad host range mutants (defective
in E1 genes) could support viral growth, led to the proposal that E1a
exerts its effect by alleviating a cellular transcription repressor that
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inhibits activation of early viral genes (Nevins, 1981). The Ela products
are not DNA binding proteins (Ferguson et al., 1985); therefore, the
transactivation of other viral genes must occur through cellular factors
that are either induced or modified by the Ela products. There is,
however, recent evidence that suggests the involvement of cis-acting
sequences of the El a region in regulating the expression of the El b unit.
The Ad host range mutant dl312 (deletion in Ela) is cis-dominant for
reduced accumulation of Elb mRNAs, and these cis-sequences may
function to render the El b unit In a transcriptionally active
conformation (Parks and Spector, 1990). The observation that Ela
defective viruses can multiply in HeLa cells at a much slower rate than
wild type viruses was instrumental in the discovery of the cis-acting
effect of Ela on its own promoter (Gaynor and Berk, 1983).
As stated earlier, the Ela transactivation of other early genes
occurs through cellular factors. The cellular transcription factor E2F is
Ela inducible and binds to sequences and causes E2 activation
(reviewed by Nevins, 1991). Deletion of either of the two E2F binding
sites (TAGA) in the E2 promoter, results in an Ela-unresponsive E2
promoter (Manohar et al., 1990). The E2F and the differentiation-
regulated transcription factor (DRTF1, which binds to E2F sites) form a
complex with the retinoblastoma (RB) cellular antioncogene product in
addition to the cellular proteins Cyclin A, pl07 and p33Cdk2 (Bandara
and Thangue, 1991; Dyson et al., 1992; Zamanian and Thangue, 1992).
The RB-E2F/RB-DRTFI complexes are active repressors of promoters
carrying E2F sites (Arroyo and Raychaudhuri, 1992; Zamanian and
Thangue, 1992; Weintraub et al., 1992). Both Ela gene products
interact with the Rb-E2F/DRTFI complexes (through CRI and II) and
cause the release of the factors, thereby alleviating the repressive effect
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of the complex and inducing transcription at the E2F/DRTF1-responsive
promoters (B andara and Thangue, 1991 ; Loeken, 1992; Howe and
Bayley, 1992; Dyson et al., 1992).
The oncogenic transformation of cells is, at least in part, a
consequence of the ability of the Ad Ela gene products to interact with
and alter the function of cellular proteins involved in the regulation of
cellular proliferation (Bandara and Thangue, 1991; Dayson et al., 1992;
Zamanian and Thangue, 1992). By releasing the sequestered factors to
activate viral genes, the Ela gene products also activate cellular genes
including the proliferation associated c-fos, c-jun and c-myc g en e s
leading to cell transformation (reviewed by Wagner and Green, 1991;
Kitabayashi et al., 1992). Perhaps, the Elb gene products augment the
Ela-induced transformation by preserving the structural integrity of
the cell and prevent cellular and viral DNA degradation in addition to
altering the function of other cellular proliferation regulatory proteins
such as the p53 (Howe and Bayley, 1992; reviewed by Horwitz, 1990;
Wagner and Green, 1991; Nevins 1991).
E4F is an Ela-induced cellular factor that is involved in the
activation of E4 transcription. Bondesson and co-workers (1992) have
demonstrated that the Ela-dependent activation of E4F, and in turn E4,
requires the CRIll and two additional domains (auxiliary regions 1 and
2 or ARt and 2) at the non-conserved C-terminus of the 289R
polypeptide.
Ela 289R polypeptide product induces the phosphorylation of
cellular transcription factors TFIID and TFIIIC. The recent finding that
the E 1a protein is associated with a serine/threonine protein kinase
activity (Herrmann et al., 1991) may account for such a phosphorylation
event. TFIID is a factor that induces transcription of viral genes that
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are transcribed by RNA polymerase II and have a TATA box near their
promoters. E1 b and IX promoters contain such binding sites for TFIID
(Parks and Spector, 1990; Babiss and Vales, 1991) whereas, the viral
associated (VA) RNA promoters have TFIIIC binding sites (Guilfoyle and
Weinmann, 1981). Ela products also regulate the transcription of E1a,
E2a, E3, E4 and some cellular genes by cellular activating transcription
factor (ATF) (Lee et al., 1987; Manohar et al., 1990; Bondesson et al.,
1992)
The transactivating effect of Ela is not limited to viral genes. In
fact, a range of cellular genes are transactivated by Ela gene products.
Cellular heat shock protein (hsp70), thymidylate synthase, PCNA and ~-
tubulin are induced by the Ela gene products (Phillips et al., 1991 ;
Morris and Mathews, 1991; Lum et al., 1992).
In addition to the positive activation of transcription, certain
regulatory elements are controlled negatively by the Ela gene products
(Nevins, 1987). At high concentration, the Ela 12S and 13S products
have been implicated in the repression of a number of promoters
including their own (Nevins, 1987), the SV40 early promoter (Velcich
and Ziff, 1985), hepatitis B virus enhancer 2 (Chen et al., 1992), the
fibronectin promoter (Nakamura et al., 1992), and the insulin promoter
(Stein et al., 1990). The N-terminus and CRII of both the 243 amino
acid and 289 amino acid polypeptides are responsible for the repression
of these promoters through cellular factors such as 010-binding protein
(OlOBP) and the BK virus enhancer factor 1 (BEF1, a member of the NFl
family)(Reifel-Millar et al., 1991; Chen et al., 1992; Nakamura et al.,
1992).
The 19 KDa polypeptide product of El b has been shown to
transactivate the expression of viral Ela, EIb, E2, E3 and E4 genes, as
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well as the cellular hsp70 gene. Although the activation of these genes
can occur In the absence of the Ela products, the presence of the 138
E 1a product enhances dramatically the transactivation role of the 19
KDa protein (Herrmann et al., 1987; Kornuc et al., 1990).
There are other regulatory controls involved in the Ad gene
expression during a productive infection in permissive cells. Although
the mechanism is unknown, DBP is required for the rapid repression (or
shut-off) of E4 expression and mediation of the rapid decay of early
mRNAs (Nevins and Winkler, 1980; Nevins, 1987; Chang and Shenk,
1990). E3 products seem to play a role in early viral gene expression as
well. Infecting cells with an Ad that is defective in the E3 region results
in the over expression of Ela gene when compared to wild type Ad
infected cells (Zhang et al., 1991). Therefore, by down-regulating the
El a expression (E1 a product renders cells susceptible to lysis by TNF
and T-lymphocytes), the E3 products are able to reduce the lysis of
infected cells by TNF and T-lymphocytes.
The E4 products have also been implicated in one of the
regulatory mechanisms of the E2a region. The 19 KDa protein product
of E4 open reading frame (ORF) 6/7 associates with E2F and activates
the transcription of the E2a region (Marton et al., 1990; Hemstron et al.,
1991, reviewed by Nevins, 1991). It appears that when the expression
of the E4 gene reaches its maximum (early in the infection) it activates
the expression of its own repressor (DBP), thereby achieving an
autoregulatory mechanism. The 14 KDa protein, E4 product, is proposed
to inhibit the activity of cellular cAMP-dependent protein kinase (PKA)
altering the phosphorylation of the Ela products. These altered Ela
proteins are unable to co-operate with cAMP to induce the DNA-binding
activity of cellular transcription factor API. Once induced, the API
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binds to cAMP responsive elements (eRE) in cAMP- and some Ela-
inducible promoters resulting in their activation (Miillr et al., 1992;
Gedrich et al., 1992). Therefore, the E4 gene product counter-balances
the effect of the Ela gene product, and plays a role in down-regulating
the activation of gene expression by Ela.
Ads encode two distinct viral associated (VA) RNAs, VA RNA I and
II, of approximately 160 nucleotides in length (reviewed by Mathews
and Shenk, 1991). In the cytoplasm of infected cells these VA RNA
molecules form stable double stranded RNA regions. The function of
these molecules (or at least of VA RNA I) is to prevent the shut-off of
host protein synthesis machinery in the late phase of viral infection
(O'Malley et al., 1989). Normally, interferons stimulate the activation of
dsRNA-activated inhibitor (DAI) by autophosphorylation. The active
DAI, in turn, inactivates the a-subunit of initiation factor 2 (eIF-2) by
phosphorylation, resulting in host protein synthesis shut-off in response
to viral infection. In the presence of VA RNA I, however, the DAI is
prevented from phosphorylating eIF-2a thereby allowing it to initiate
polypeptide synthesis and .participate in viral late mRNAs translation
(Mellits et al., 1990; 1992).
Viral gene expression IS also affected by the topology of the viral
DNA (Wong and Hsu. 1989). Banerjee and Spector (1992) have shown
that Ela and El b are synthesized 2 to 7 fold more abundantly from
supercoiled DNA than from a linear template.
In permissive cells, the result of all of these complicated
regulatory pathways is a balanced viral polypeptide pool that sets the
stage for viral DNA replication and late gene expression.
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1.6 Infection and Viral DNA Replication:
Ads recognize and attach to host cells through VIrIon fiber-specific
host cell receptors. Once the particles are attached to the receptors,
they are transported to the cytoplasm in receptosomes by an endocytic
process (Varga et al., 1991). The change in pH (drops to 5.5) in these
endosomes alters the conformation of the viral particle resulting in the
release of an active core in the cytoplasm. The active core is then
transported by microtubules to the nuclear pores, approximately one
half hour post infection, where the DNA enters the nucleus leaving
behind many of the viral proteins. Upon entering the nucleus, the viral
DNA is transcribed into mRNAs under the tight control of viral and
cellular factors. Viral RNA synthesis has recently been shown to be
localized mainly at the periphery of the replicative zone and, to a lesser
extent, few other viral specific nuclear inclusion sites (Puvion-Dutilleul
and Puvion, 1991). The result of translating the viral transcripts into
polypeptides is the accumulation of proteins and factors required for
viral DNA synthesis (Varga et al., 1991).
The development of in vitro replication systems for Ad replication
has contributed significantly to the understanding of the mechanisms
involved in DNA replication (Challberg and Kelly, 1979). Ad DNA
replication occurs in inclusion bodies in the nucleus of infected cells
(Murti et al., 1990; Moen et al., 1990; Puvion-Dutilleul, 1991). Viral
DNA replication starts at one of the ends of the DNA molecule and
proceeds in the 5' to 3' direction by a semiconservative strand
displacement mechanism (Challberg and Kelly, 1979). The location of
the core origin of the replication site has been mapped to nucleotides 1-
18 of the DNA molecule (DePamphilis, 1988; Dobbs et al., 1990). The
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adjacent 33 nucleotides (19-51) constitute the auxiliary elements of the
origin of replication that are required for the binding of host factors
involved in replication (Kenny et al., 1988; O'Neill and Kelly, 1988;
DePamphilis, 1988). Synthesis of viral DNA requires at least 4 host
factors, 3 Ad encoded proteins and the initiation sequences on the viral
genome.
All nascent daughter DNA strands, extracted from infected cells
before viral packaging, were found to be covalently linked to an 80 KDa
protein at the 5' terminus (Challberg et al., 1980). This protein, like the
55 KDa terminal protein (TP), is linked to the DNA by a serine
phosphodiester bond and shares a number of tryptic peptides with the
55 KDa TP (Challberg et al., 1980; Desiderio and Kelly, 1981). In fact the
80 KDa polypeptide is the precursor for the 55 KDa TP. The conversion
from the 80 KDa preterminal protein (pTP) to the 55 KDa TP was found
to occur by virally encoded 23 KDa protease that cleaves the pTP during
packaging of the DNA into preformed viral capsids (Enomoto et al.,
1981; Challberg and Kelly, 1981). Although the N-terminus of the pTP
is cleaved during virion assembly, it is involved in the formation of the
replication initiation complex or in the folding of the pTP that is
essential for protein-protein or protein-DNA interactions required for
the priming of DNA synthesis (Fredman et al., 1991; Roovers et al.,
1991). The pTP binds to a dCMP residue to form a complex that is used
as the primer for DNA synthesis (Lichy et al., 1981).
Cytoplasmic extracts from cells infected with Ad contain pTP
associated with polymerase activity. This activity was shown to be
associated with a 140 KDa DNA polymerase that was different from all
cellular DNA polymerases. This polymerase was found to be the
product of the viral E2b region (Lichy et al., 1982). In addition to DNA
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synthesis, the Ad DNA polymerase is also responsible for catalysing the
transfer of the dCMP directly on the J3-0H of the serine residue of the
pTP to form the pTP-dCMP initiation primer complex.
The E2a encoded DBP (figure 3), which binds ss-DNA through a
ZInc motif at the conserved c-terminus of the protein (Eagle and Klessig,
1992) is another viral protein that is essential for viral DNA replication
both in vivo and in vitro (Ikeda et al., 1981). In addition to the obvious
role that the DBP plays in protecting the displaced ss-DNA molecule
from nuclease activity, the DBP also plays a role in stimulating the
formation of the initiation complex and in the elongation step by
interaction with the Ad DNA polymerase (Tsuji et al., 1991).
As previously stated, a number of cellular factors are required for
Ad DNA replication. Nuclear factor I (NFl) is a 47 KDa cellular protein
that was shown to complement Ad DNA replication and stimulate the
formation of pTP-dCMP initiation complex (Nagata et al., 1982). The
utilization of nuclease protection assays identified the binding site for
NFl to be nucleotides 19-42 of the Ad genome (Kenny et al., 1988). The
binding of NFl to this sequence generates single stranded regions
allowing the pTP-dCMP complex to bind to the ori site at residues 1-18
of the genome (Nagata et al., 1983; Dobbs et al., 1990).
Nuclear factor II (NFII) is cellular protein which is required for
full elongation of Ad DNA during synthesis. NFII has been shown to be
a topoisomerase that is required to alleviate the stress generated by the
unwinding of the DNA and allow for the complete elongation of the
daughter DNA strand (Horwitz, 1990). In addition to the NFII
topoisomerase activity, cellular topoisomerases I and II have been
shown to play a role in the replication and packaging of Ad DNA (Wong
and Hsu, 1990). Topoisomerase II may also function to release Ad DNA
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molecules from the nuclear matrix to which they bind through the
terminal protein at the end of the replication cycle (Schaack et al.,
1990). Nuclear factor III, a 92 KDa cellular polypeptide isolated from
nuclei of uninfected HeLa cells, is another protein that is required for
the efficient initiation of viral DNA replication (O'Neill and Kelly, 1988).
The currently accepted model of Ad DNA replication is a modified
rolling circle model (figure 6). The circle is formed by the non-covalent
interaction between the terminal proteins at both ends (reviewed by
Horwitz, 1990). Sakaguchi (1990) suggested that not only the
interaction of the terminal protein, but also the interaction of the site-
specific host factors (such as the NFl, II, and III) are important in
forming the circle. In his Racket Frame model, Sakaguchi (1990)
suggests that these factors act as juxtaposing cohesive proteins that
interact together, after binding to the DNA, to form a quadruple-
stranded DNA of the two identical double-stranded ends. The first
round of replication starts at either end but subsequent rounds always
start at the same end as the first round.
The initiation of viral DNA replication takes place when the
initiation complex binds to the origin of replication (residues 1-18) of
the DNA molecule. The initiation complex is composed of the pTP
covalently linked to a dCMP residue through a serine phosphodiester
linked to the 5' OR of the dCMP (Lichy et al., 1981). This reaction is
catalized by the Ad DNA polymerase which, itself, is part of the
initiation complex. In fact, Ad DNA polymerase has been shown to
interact not only with the pTP, but also with NFl (Temperley and Hay,
1992). The binding of NF I to its site, which is enhanced by the binding
of the Ad DBP to the DNA template (Kenny and Hurwitz, 1988; Bosher et
al., 1991), has been demonstrated to increase the stability of the
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Figure 6: Schematic representation of the modified rolling-circle model
for adenovirus DNA replication. Stages I to VI are for replication
of the ds DNA molecule and stage VII is for replication of the
displaced ss DNA molecule ( from Horwitz, 1990).
Ad pol-pTP preinitiation complex by ten times thereby enhancing the
process of initiation of replication (Mul and Van der Vliet, 1992). NF I
and the TP are believed to play an important role in generating a
single-stranded DNA region at the origin of replication (Kenny et al.,
1988; Kenny and Hurwitz, 1988). This would allow for the binding of
the initiation complex to the origin of replication and initiate the DNA
synthesis at the first residue (which is the C attached to the pTP). The
elongation of the new strand by Ad DNA polymerase displaces the
parental strand with the same polarity. Topoisomerases (and/or NF II)
are required to release the stress of unwinding of the DNA caused by
the continuous synthesis. The Ad DBP protects the displaced strand
from nuclease digestion. When the displaced strand is freed from the
complex, it presumably forms a panhandle structure through the
inverted terminal repeats (ITRs) and, according to the Racket Frame
m~del, the host cell factors. One line of evidence for the formation of
the panhandle on the displaced strand was the rearrangement of the
duplicated ITR sequences, at the left end of an Ad5 deletion mutant,
during replication (Haj-Ahmad and Graham, 1986). The panhandle is a
double stranded DNA structure with a 55 KDa protein at the 5' end
identical to the structure of the parental dsDNA molecule. Initiation of
replication on the displaced strand occurs in the same manner as
mentioned and elongation proceeds displacing the DBP bound to DNA.
This mechanism (figure 6) results in the synthesis of two double
stranded DNA molecules (reviewed by Horwitz, 1990; Sakaguchi, 1990).
Viral DNA replication signals the switch in transcription from
early to late transcription units. Larsson and co-workers (1991) have
recently shown that the switch from early to late mRNA splice site
choice is activated by DNA replication rather than protein synthesis. In
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addition, Toth and colleagues (1992) have also shown that viral DNA
replication is essential for the interaction between the major late
promoter (MLP) and its transcription activation factor, MLPF/USF.
Another factor that was shown to be important in the activation of
the late viral genes is the topology of the template (Banerjee and
Spector, 1992; Ohba et al., 1992). Perhaps the replication of viral DNA,
which causes unwinding of the DNA, results in a conformational change
in the template that would favor the transcription of late genes by
allowing the transcription factors to bind the late promoter.
1.7 Late Gene Expression and Virion Assembly:
There are 5 late transcription units, Ll, L2, L3, L4 and L5,
controlled by the MLP the activation of which is induced by viral DNA
replication (Lewis et al., 1975; Larsson et al., 1991; figure 3). The
distinct mRNA families produced by each unit have the same poly(A)
sites with the exception of L5 which has two poly(A) sites (reviewed by
Horwitz, 1990; figure 3). The different mRNA species produced from
each of the late units are generated by alternative splicing of different
5' splice don'or sites to the common 3' splice acceptor site of the
tripartite leader sequence immediately down stream of the MLP. Most
of the gene products of the late phase are structural proteins; however,
some early proteins such as DBP are still synthesized in late phase.
Some of the late transcript products are non-structural proteins such as
the 100 KDa, 50 KDa and 39 KDa proteins, which are involved in the
assembly of the virus. The 100 KDa non-structural protein is believed
to be a scaffolding protein for hexon capsomer assembly in the
cytoplasm whereas the 50 KDa and 39 KDa proteins are scaffolding
proteins involved in the formation of the immature capsid in the
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nucleus of infected cells (reviewed by Horwitz, 1990). Expression of the
100 KDa protein is also necessary for efficient initiation of translation of
the other late mRNAs during the late stages of infection (Hayes et al.,
1990). The Ll 52/55 KDa products are also believed to be scaffolding
proteins since heterodimers of these proteins are present in the empty
capsid (50 to 100 copies) and in the young virions (1 to 2 copies) but
not in the mature viral particles (Hasson et al., 1992). In fact, Ad
mutants in the 52/55 KDa gene are defective in the assembly of
infectious virions (Hasson et al., 1992). The L3 transcription unit
encodes a 23 KDa protease that is responsible for the cleavage of the
pVI, PVII, PVIII and pTP into mature peptides (VI, VII, VIII and TP) in
the last step of assembly to produce the mature viral particles. These
precursor proteins can be efficiently and correctly cleaved by proteases
isolated from different adenovirus serotypes suggesting a high degree
of conservation in the Ad protease gene (Houde and Weber, 1990).
Accumulation of viral DNA and viral structural and other
polypeptides signals the initiation of the assembly and packaging
processes. Assembly of the progeny viral particles takes place in
nuclear compartments distinct from replication centers (Hasson et al.,
1992). The viral DNA is inserted into a preformed capsid in a polar left
to right fashion. In support of this, Grable and Hearing (1992) have
recently shown the presence of five cis-acting, AT rich packaging signal
motifs (called the A repeats) at the left end of the viral genome. Based
on these findings and the fact that the distance separating these motifs
is essential for efficient packaging, Grable and Hearing proposed that
the packaging elements bind to trans-acting packaging factors to form a
nucleoprotein complex that is recognized by the packaging machinery of
the virus. Ghosh-Choudhury and co-workers (1986) have described an
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Ad5 mutant with deletion in the El, that extended into the IX gene, that
was defective in packaging the full length genome. Upon restoration of
the IX gene sequences, the defect in the packaging was corrected
suggesting an important role for the structural IX protein in packaging
of full-length genome. The lytic cycle of Ad in permissive cells leads to
the production of approximately 10,000 progeny virions from each
infected cell within 36 hours of initial infection.
1.8 Bovine adenoviruses:
The first bovine adenovirus (BAV) prototype was isolated by Klein
and colleagues in 1959. Since that time, BAVs have been isolated, all
over the world, from a number of animal species including free-living
African buffalo (Baber, 1981), sheep (Belak and Palfi, 1974; Belak et al.,
1986) and fallow deer (Boros et al., 1985). BAV infection can result in
keratites, conjunctivitis, "respiratory and enteric diseases that result in
weak calf syndrome in newborn calves and ad.ult cattle (Key and
Derbyshire, 1984; Scanziani et al., 1989, Reed et al., 1978; Lehmkuhl et
a 1., 1975). BAV infections causes poor weight gain, poor dairy
production and increased infant mortality, and thus they are of great
economical consequence.
BAVs belong to the Mastadenovirus genus of the family
Adenoviridae. The nine currently accepted BAV serotypes are divided
into two subgroups: subgroup I includes serotypes 1, 2, 3 and 9, and
subgroup II includes serotypes 4 to 8 (Bartha, 1969). This classification
scheme was based on at least four different criteria: (i) the presence of
a complement fixing antigen common to M astadenoviruses (B artha,
1969, Adam et al., 1988), (ii) the ability to multiply in different cell
cultures (Bartha, 1969; Benko et al., 1989), (iii) homology with other
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adenoviruses (Hu et al., 1984a; Benko et al., 1990) and (iv) SIze and
restriction enzyme pattern of the genome (Benko et al., 1988).
Bovine adenovirus type 3 (BAV3) was first isolated by Darbyshire
and co-workers from the conjunctiva of an apparently healthy cow
(Darbyshire et al., 1965). Unlike other BAVs, BAV 3 causes oncogenic
transformation in newborn hamsters and mouse cell lines (Darbyshire
et al., 1966; Igarashi et al., 1978; Motoi and Ogawa, 1985). Like other
adenoviruses, the transforming region of BAV3 has been localized at the
left end (0 to 11.9%) of the viral genome (Igarashi et al., 1978; Niiyama
et al., 1981). BAV3 is a nonenveloped icosahedral-shaped particle of
approximately 75 nm in diameter (Niiyama et al., 1975). Its genome
consists of a 35,000 base pairs linear double-stranded DNA molecule
(Niiyama et al., 1975; Benko et al., 1988; Benko and Harrach, 1990) that
has 48% G:C content (Panigraphy et al., 1977) and 195 bp inverted
terminal repeats (Shinagawa et al., 1987).
Hybridization studies carried out between BAV3 and human
adenovirus type 2 (Ad2) revealed an extensive homology between 10
and 80% of the viral genomes (Hu et al., 1984a, b; Kurokawa et al.,
1978). Hu and colleagues (1984a) also showed that the majority of
BAV3 late transcripts have the same orientation and similar location
when compared to Ad2 late transcripts. In fact, BAV3 has a higher
degree of homology with Ad2 than with subgroup II BAVs (Benko e t
al.,1990). Based on these reports, BAV3 seems to be very similar to
human adenoviruses in terms of gene structure and organization.
1.9 Restriction Endonuclease Mapping:
Restriction endonucleases (RE) are proteins that recognize specific
dsDNA sequences and introduce nicks in both strands. Since they were
43
first isolated (Meselson and Yuan, 1968), two types of REs have been
described. Type I refers to those enzymes that recognize specific DNA
sequences and introduce nicks at non-specific sequences near the
recognition sites. Type II enzymes are those that recognize specific DNA
sequences and nick the DNA at that sequence (Kelly and Smith, 1970;
reviewed by Boyer, 1971; Nathans and Smith, 1975). The discovery of
restriction enzymes was one of the most, if not the most, important
event in the history of molecular biology. Today, RE are the main tool in
recombinant DNA technology. Furthermore, REs are becoming
increasingly useful in the identification of new isolates of
microorganisms, and disease causing agents (Adair and McFerran, 1976;
Benko et al., 1988; Adrian et al., 1986 and 1990).
Restriction enzyme mapping is an essential first step in the
characterization of chromosomes. Prior to the use of gel electrophoresis,
the location of a restriction site was determined relative to partially
denatured single-stranded landmarks (AT rich regions) on the DNA by
electron microscopy (Mulder and Delius, 1972). The molecular size of
restriction fragments was determined by measurement of the lengths of
the fragments relative to a DNA molecule of known size by electron
microscopy, or by sedimentation of the fragments in alkaline or neutral
sucrose gradients (Danna and Nathans, 1971; Griffin, 1981; reviewed by
Nathans and Smith, 1975). More recently, the most widely used method
for detecting and estimating the size of restriction fragments is agarose
or polyacrylamide gel electrophoresis (Sharp et al., 1973; Meyers et al.,
1976).
Restriction mapping refers to the process by which the locations of
recognition sites for various REs are determined in a target DNA.
Restriction mapping can be accomplished by various methods.
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Determination of the base paIr sequencing of the target DNA is the most
accurate method. This method, however, is highly costly. Another
method involves the cloning of restriction fragments into cloning
vectors and restriction mapping the cloned fragments. The cloning
method is the most widely used method for a number of reasons that
include: (i) it is an intermediate step in sequencing, (ii) in some cases,
cloned fragments are easier and less expensive to produce than the
target gene or chromosome, (iii) cloned DNA fragments are easier to
subject to molecular manipulations (such as deletions, insertions,
rearrangement, etc.) than the intact gene or chromosome, and (iv) much
faster and less expensive than sequencing a large DNA molecule.
1.10 Purpose of the Investigation:
To study gene structure and organization of BAV3 in detail, it is
necessary to construct a detailed restriction endonuclease map of the
viral genome. Furthermore, the availability of detailed restriction maps
would facilitate the construction of BAV3 based gene transfer vector(s)
which is the overall objective of our research group. To date, there are
only five restriction enzyme (RE) maps of BAV3 published (Hu e t
al.,1984a; Kurokawa et al., 1978; Zalmanzon et al., 1982). Therefore, the
aim of this study was to clone the BAV3 genome and construct detailed
restriction endonuclease maps of the BAV3 genome.
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Chapter 2: Methods and Materials
2.1 Cells and Viruses:
Madin-Darby bovine kidney (MDBK) cells (a generous gift from J.
b. Derbyshire, University of Guelph, Guelph, Ontario, Canada) were
grown and maintained in 150 mm plates in alpha-minimum essential
medium (a-MEM) supplemented with 10% fetal bovine serum (FBS,
Gibco Laboratories), 0~29 Jl g/ml L-glutamine, 0.225% sodium
bicarbonate and 1.5% antibiotic-antimycotic (10,000 units/ml penicillin,
25 Jl g/ml amphotericin Band 10,000 Jl g streptomycin; Gibco
Laboratories). The cells were grown in a humid 37°C incubator under
constant atmospheric pressure of 5% C02.
The BAV3 strain used in this study was the prototype strain WBR-
1 (also obtained from J. B. Derbyshire,University of Guelph).
2.2 Bacterial Strains:
Escherichia coli (E. coli) strain DH5a (Bethesda Research
Laboratories) was used as a host for the constructed recombinant
plasmids. Its genotype is supE44 ~lacU169 (<1>80 lacZ ~M15) hsdR17
recAl endAI gyrA96 thi-l relAI. The methylation deficient E. coli
strain GM48 (dam-jdcm-) (gift from F.L. Graham, McMaster University,
Hamilton, Ontario, Canada), was also used as a host for some of the
recombinant plasmids. Its genotype is th leu thi lacY galK galT ara tonA
tsx dam dcm supE44.
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2.3 Viral Propagation and Purification:
Semiconfluent 150 mm dishes of MDBK cells were infected with
approximately 10 plaque forming units (pfu)/cell of BAV3 and
maintained in a-MEM supplemented with 5% FBS. When approximately
80-90% (72-100 h) cytopathic effect (CPE) was observed, the cells were
harvested in phosphate buffered saline (PBS). The cells were pelleted
at 1,000 rpm (IEC) for 15 min at 4°C. The cell pellet was resuspended
in 3 ml PBS and subjected to 5 freeze-thaw cycles in liquid N2.
Following the freeze-thaw cycles, the solution was made up to a final
volume with 15 mM Tris (pH 8.0). For every 3.5 ml of 15 mM Tris (pH
8.0) added to the lysate a total of 1.8 ml 15 mM Tris (pH 8.0) saturated
with CsCI was added (final density was approximately 1.34 g/ml). The
lysate was centrifuged at 35,000 rpm (73,000 g) for 20 h at 4°C in a
Beckman TLA-IOO.3 fixed angle rotor. The viral particle band was
collected and dialyzed extensively against 50 mM Tris pH 8.0 at 4°C.
2.4 Viral DNA Extraction
DNA from purified viral particles was extracted according to the
procedure described by Pettersson and Sambrook (1973). The purified
viral particles were collected from the dialysis tubing and added to 0.45
ml of lysing buffer (0.01 M Tris; 0.01 M EDTA; 0.4% sodium dodecyl
sulphate (SDS); pH 8.0). An aliquot of 0.05 ml of lOX pronase (5 mg/ml
in 0.01 M Tris, pH 8.0) was added, and the solution was incubated at
37°C for 2 h, followed by extraction with phenol:chloroform:isoamyl
alcohol (25:24:1 v/v). The aqueous phase was combined with 2
volumes of cold 95% ethanol and incubated at -20°C for 15 min. The
DNA was precipitated by centrifugation at 12,000 rpm for 5 min at
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room temperature in a microcentrifuge. The ethanol was aspirated, and
residual ethanol was evaporated at 37°C for 5 to 10 min. The DNA
samples were then resuspended in the appropriate volume of TE buffer
(10 mM Tris.HCI, 1 mM EDTA, pH 8.0) and stored at -20°C.
DNA from BAV3 infected cells was harvested according to the
method described by Hirt (1967) as modified by Haj-Ahmad and
Graham (1986) when maximum CPE was observed. The procedure
involved harvesting the infected cells from 150 mm dishes in PBS and
pelleting them at low speed (800 to 1,000 rpm) at 4°C. The cell pellets
were treated with lysing buffer and pronase, as described above, for 12
h. The samples were phenol:chloroform:isoamyl alcohol extracted and
the DNA was collected by ethanol precipitation. Again, the DNA was
dried, resuspended in TE buffer and stored at -20°C.
2.5 Construction of Recombinant Plasmids Carrying
Internal BAV3 Genomic Inserts:
The recombinant plasmids were generated by ligating restriction
fragments of BAV3 DNA to the linearized plasmid vector pUC19.
Restriction enzymes were inactivated by phenol:chloroform:isoamyl
alcohol extraction followed by ethanol precipitation. Ten to fifty ng of
digested BAV3 DNA was mixed with approximately 100 ng of linearized
pUC19 in the presence of ligation buffer (10 mM MgCI2, 20 mM
dithiotheitol, 50 mM Tris, 1 mM ATP, pH 7.5), 1 to 3 units of T4 DNA
ligase (Promega) and distilled water. A typical reaction was carried out
for 1.5 to 2 h at room temperature or overnight at 15°C. The ligation
mixture was then stored at _20° C until it was used in the
transformation of E. coli.
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2.6 Construction of Recombinant Plasmids Carrying
TerlDinal BAV3 GenolDic Inserts:
Cloning of the end fragments in the method described above was
not possible due to the presence of the 55 KDa TP at the 5 f end of each
DNA molecule which prevents DNA-DNA ligation. The protein-DNA
bond was cleaved using a modified Desiderio and Kelly (1981) sodium
hydroxide hydrolysis method. Approximately 100 Ilg of CsCI-purified
viral DNA was digested with the restriction enzyme Bam HI. The
digested DNA solution was brought to 50 mM NaOH in a total volume of
100 III and incubated at 65°C for 1 h. The reaction mixture was then
neutralized by adding 10 J.11 of 500 mM Tris.HCI (pH 6.5) and 100 J.11 of
50 mM Tris.HCI (pH 8.0). The reaction solution was allowed to anneal at
65°C for 5 h followed by phenol:chloroform:isoamyl alcohol extraction.
The aqueous phase was brought to 0.3 M sodium acetate (pH 7.5) and
the DNA was ethanol precipitated. The DNA pellet was then dried and
resuspended in 20 J.11 TE buffer. This resulted in the generation of
terminal fragments with a blunt end and a B amHI cohesive end.
A 5 J.11 sample of the treated DNA was combined with,
approximately, 5 J.1g of pUC19 digested with BamHI (cohesive end) and
HincII (blunt end). The DNA mixture was ligated for 16 h at 15°C using
200 units of T4 DNA ligase. The ligation reaction was then used to
transform DH5cx and the resulting transformants were screened for
recombinant plasmids carrying the terminal fragments by the colony
hybridization technique.
2.7 Bacterial Transformation:
Transformation of the E. coli was carried out as described by
Goodman and MacDonald (1979). Essentially, one colony of E. coli was
grown overnight in 2 ml Luria Broth (LB) (10% Bacto-Tryptone, 5%
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Bacto-Yeast Extract and 10% NaCI) in a 37°C shaking water bath. A 0.5
ml aliquot of the overnight culture was inoculated into 50 ml LB and
grown to mid log phase (2.5 to 3 h). The cells were then pelleted at
3,500 rpm for 15 mIn at 4°C and resuspended in 25 ml of ice-cold
transformation buffer (75 mM CaCI2, 5 mM Tris.CI, pH 7.6) and
incubated on ice at 4°C overnight.· The cells were pelleted at 3,500 rpm,
resuspended in 1 ml ice-cold transformation buffer. Samples (100 JlI)
were transferred to 1.5 ml microcentrifuge tubes. One to ten Jlg of
transforming DNA was added to the cells and incubated on ice for 30
mIn. The cells were then heat-shocked for 2 min at 42° C and
subsequently incubated on ice for 2 min. The cells were allowed to
recover for 1 h at 37°C in total volume of 1 ml of SOC medium (2%
bacto-tryptone, 0.5% yeast extract, 10 mM NaCI, 2.5 mM Kel, 10 mM
MgCI2, 10 mM MgS04 and 20 mM glucose). A serial dilution of the cells
was made and 100 JlI portions were plated on LB agar (2% agar) plates
supplemented with 25 to 50 Jlg/ml ampicillin and 0.3 Jlg/ml X-gal (5-
bromo-4-chloro-3 -indolyl ~ -D-galactopyranoside). Transformant
colonies were observed after the plates were incubated at 37°C for,
approximately; 15 h.
2.8 Colony Hybridization:
LB agar plates containing E. coli transformants were replica-plated
onto 82 mm nitrocellulose membranes (Schleicher and Schuell). The
master plates were incubated for an additional 4 h at 37°C and stored at
4°C. The nitrocellulose membranes were placed on filter paper soaked
with 10% SDS for 3 min to lyse the cells followed by 5 min on filter
paper soaked with denaturing solution (0.5 M NaOH, 1.5 M NaCI) to
denature the released DNA. The membranes were then placed on filter
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2.9 Plasmid DNA Extraction:
Recombinant plasmid DNA was extracted from bacterial
transformants using the alkaline lysis method (Sambrook et al., 1989).
A bacterial colony was grown in 2 ml LB medium for 8 to 12 h at 37°C
with shaking. Bacterial cells were pelleted at 10,000 rpm for 1 min and
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the cell pellet was resuspended in 100 JlI of lysozyme solution (10 mM
EDTA, 50 mM glucose, 25 mM Tris.HCI, pH 8.0) that contained 2 mg/ml
lysozyme (Sigma). The sample was incubated on ice for 20 to 30 min
followed by the addition of 200 JlI of alkaline-SDS (0.2 N NaOH and 1.0%
SDS) at room temperature for 10 to .15 min. An aliquot of 150 JlI of 3 M
sodium acetate (pH 4.8) was added and the sample was incubated on ice
for a further 20 to 30 min. The sample was centrifuged at 10,000 rpm
for 5 min and the supernatant was ethanol precipitated using two
volumes of -20°C, 95% ethanol. The resulting DNA pellet was
resuspended in 400 J.11 of distilled water and subjected to an additional
ethanol precipitation. The resulting plasmid DNA was dried,
resuspended in TE buffer and stored at -20°C.
2.10 Restriction EnzyIDe Digestion and Analysis:
The -restriction enzymes used in this study (purchased from either
Promega or Boehringer Mannheim) were used according to the
supplier's recommendation. A 10 JlI DNA sample (1 to 10 Jlg) was mixed
with 2 JlI of lOX restriction enzyme buffer as supplied by manufacture
(content of buffer differs from one enzyme to another), 5 to 10 units of
the restriction enzyme and the volume was made up to 20 JlI with
double distilled water. A typical restriction digestion reaction was
carried out for 3 to 5 h at 37°C.
Samples were loaded on the agarose gels In loading buffer (20%
glycerol, 2% SDS, 0.05% bromophenol blue) and the restriction fragments
were electrophoretically separated on 0.8 to 1.0% agarose gels at 5
V/cm in TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA; pH
8.0). Following electrophoresis, the gels were stained with ethidium
bromide (0.3 to 1 Jlg/ml of gel), placed on a UV transilluminator and
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photographed with a mounted Polaroid Land camera with Polaroid Type
57 film. The sizes of the fragments were graphically estimated using "A-
Hi ndIII (Promega) or Ad5-H i ndIII digests as molecular-weight
markers.
2.11 DNA Sequencing:
DNA sequences were determined according to the dideoxy
nucleotide (ddNTP) chain termination method described by Sanger and
co-workers (1977). All the materials used were purchased (United
States Biochemicals) in the form of a sequencing kit known as
"Sequenase Version 2.0 Kit" and used according to the suppliers
recommendations. Plasmid DNA was denatured in 0.2 M NaOH, 0.2 mM
EDTA for 30 min at 37°C, neutralized in 0.3 M sodium acetate (pH 4.8)
and precipitated in 2 volumes 95% ethanol for 15 min at -70°C. The
denatured plasmid DNA concentration was determined from its
absorbance at 260 nm (1 OD unit=35 J.1g of DNA/ml of solution).
Approximately, 5 Jlg of denatured plasmid DNA (template) was
annealed to 0.5 picomoles of a 16-mer oligonucleotide primer in 10 JlI of
IX Sequenase buffer (200 mM Tris.HCI (pH 7.5), 100 mM MgCl2 and 250
mM NaCI). The primer is specific for a sequence adjacent to the
polycloning site of pUC19. Annealing was carried out at 65°C for 2 min
followed by gradual cooling to room temperature over 15 to 30 min.
The template-annealed primers were extended in 6 J.1 M DTT
(dithiotheitol), 0.2 J.1M of each of the dNTPs (dCTP, dGTP, dTTP and [a-
32p or a- 35 S] dATP) and 3.25 units of Sequenase Version 2.0
polymerase. Following extension at room temperature for 2 to 5 min,
3.5 JlI samples of the reaction mix were combined with 2.5 JlI of each of
four termination mixtures (80 JlM of each of the four dNTPs, 8 JlM of
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one of the four dideoxy NTPs, 50 mM NaCI) and the reaction was carried
out at 37°C for 5 min. The termination reactions were stopped by
adding 4 JlI of stop solution (95% formamide, 20 mM EDTA, 0.05%
bromophenol blue, 0.05% xylene cyanol FF) and stored at -20°C.
The sequencing gel matrix was 60 ml of 6% Long Ranger (J. T.
Baker), 8 M urea and IX TBE buffer (89 mM Tris, 89 mM boric acid, 2
mM EDTA; pH 8.0) that was polymerized in the presence of 250 JlI of
10% ammonium persulfate and 25 J.11 of TEMED (N,N,N',N'-
tetramethylethlene diamine; Bio-Rad). Samples (2.5 to 3 JlI) of the
sequencing reactions were heated to 75 to 80°C for 2 min immediately
prior to loading on the warmed gels. A shark tooth comb was used to
hold samples in place. Electrophoretic separation was carried out at
constant current of 1.25 A/em in 0.6X TBE buffer for 1.5 to 2 h. Gels
were lifted off the glass plates by adsorption to #3 Whatman filter
paper, covered with "Plastic Wrap" and vacuum dried at 80°C for 20
min in a Bio-Rad model 583 gel drier. Dried gels were exposed to Kodak
X-OMAT X-ray film overnight for 32p labeled samples and 72 h for 35S
labelled samples.
2.12 32P-Labeling of BAV3 DNA:
Restriction endonuclease fragments of BAV3 were labeled with a
[32p] dCTP/[32p] dATP cocktail using the Klenow (Promega) filling
reaction as described by Sambrook and colleagues (1989).
Approximately, 1 Jlg of the viral DNA was digested with a restriction
enzyme for 3 to 4 h at 37°C in total volume of 20 JlI. The resulting
digestion mixture was made up to 40 JlI with 4 JlI of DNA polymerase
buffer (500 mM Tris, 70 mM MgCI2, 70 mM 2-mercaptoethanol, pH 8.0),
0.5 JlI of Klenow (1 unit/JlI), 2 JlI of each of 100 mM dGTP and 100 mM
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dTIP, 3 JlI of [32p]dATP and 3 JlI of [32p] dCTP and 5.5 JlI of distilled
water. The reaction was stopped after a 15 min incubation at 37°C,
with 5 JlI loading buffer (20% glyc_erol, 2% SDS, 0.05% bromophenol
blue). The resulting radiolabelled fragments were separated
electrophoretically on 1.1 % agarose gels. The gels were dried onto
Whatman paper and exposed subsequently to Kodak X-OMAT AR film.
Chapter 3: Results
3.1 Molecular Cloning of the BAV3 DNA:
Molecular cloning is a process that refers to the insertion of DNA
fragments into a suitable vector and amplifying the recombinant vector
in an appropriate host. Cloning allows for easy molecular manipulation
and characterization of a DNA fragment. The objectives of this study
were to clone the BAV3 DNA in the form of restriction fragments and to
construct a detailed restriction enzyme map of the BAV3 genome. The
following sections will describe the strategies used and the the results
obtained to reach these objectives.
3.1.1 Cloning of BAV3 EcoRI and XbaI Fragments:
The digestion of Hirt's extracted BAV3 DNA resulted in seven
fragments (A to G) ranging in size from 8.7 to 1.2 Kbp. These fragments
were more intense (as viewed on ethidium bromide stained agarose
gels) than the contaminating cellular genomic DNA that usually results
from the extraction procedure. Although it was not certain, these
fragments were presumed to be of viral orIgIn. These fragments are of
a convenient size range for molecular cloning and restriction enzyme
mapping.
BAV3 DNA was digested with EcoRI, to completion, and the
resulting fragments were cloned into the unique E co RI site of the
bacterial cloning vector pDC 19 according to the strategy outlined in
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Figure 7. Schematic representation of the cloning strategies
employed in the cloning of the BeoRI (A) and the Xbal (B)
fragments and the plasmids constructed with these strategies.
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figure 7A. The strategy involved combining the EcoRI-digested BAV3
DNA with EcoRI-linearized pUCl9 in the presence of T4 DNA ligase. The
ligation mix was used subsequently to transform competent E. coli
strain DH5a. Cells containing recombinant plasmids were selected on
medium containing ampicillin and X-gal. The plasmid DNA, isolated
from each of the transformant colonies, was digested with E co RI and
electrophoretically separated on 0.8% agarose gels. The inserts within
each of the plasmids were identified by their co-migration with E coR I
digest of the viral DNA on agarose gels. Out of approximately 250
colonies screened, six colonies contained recombinant plasmids with
inserts that co-migrated with BAV3 EcoRI fragments.
Plasmids pEA26 (figure 8), pEB71 (figure 9A), pEC20 (figure 9B),
pEC23 (figure lOA), pEDI (figure lOB) and pEF73 (figure lIB) contained
BAV3 EcoRI fragments A, B, C, C, D and F respectively. Plasmids pEC20
and pEC23 contain the same insert, EcoRI fragment C, oriented in the
opposite direction with respect to the polycloning site of the vector. All
of the inserts were considered to be of viral origin based on their co-
migration with five of the seven BAV3 EcoRI fragments on agarose gels.
The two remaining fragments (E and G) were presumed to be the ends
of the viral genome. This was based on the inability to clone these
fragments and the presence of these fragments at submolar quantities
on agarose gels. This is probably due to the presence of residual TP
peptides at the 5' termini of the genome which would prevent DNA-DNA
ligation and, in the case of gel electrophoresis, prevent some of the DNA
molecules from entering the gel matrix.
Each of the recombinant plasmids was digested with B amHI, C lal,
EcoRI, Hindlll, Kpnl, Notl, NspV, Pstl, Pvul, Sail, Xbal and Xhol. The
resulting fragments were separated on agarose gels and photographed
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Figure 8. A photograph of a 0.9% agarose gel of plasnlid pEA26
digested with HindIII, EcoRI, B amHI, XbaI, PstI, Sail, KpnI and
CIaI, lanes 3 to 10, respectively (A). Lanes 1 and 2 are Ad5-
HindIII and pUC19-HindIII markers, respectively. Panel B shows
the restriction map of plasmid pEA26.
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F i gu r e 9 : Restriction endonuclease maps of the plasmid pEB 71 (A)
carrying BA V3 EcoRI fragment B and the plasmid pEC20 (B)
carrying the BA V3 EcoRI fragment C. The position of each of
the restriction sites is indicated in base pairs relative to the
nucleotide 1 of the vector pUC19.
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Figure 10: Restriction endonuclease maps of the plasmid pEC23 (A)
carrying BAV3 EcoRI fragment C and the plasmid pEDl (B)
carrying the BA V3 EcoRI fragment D. The position of each of the
restriction sites is indicated in base pairs relative to nucleotide 1
of the vector pUC19.
62
pXA 180
(18.4 Kbp)
EcoRI(396)
Xbal(423)
PStl(650)
Kpnl(1350)
,~c.oo:a~ Notl(1950)
~-PStl(2150)
ECORI(2450)
Notl(2750)
Notl(3250)
Notl(4050)
PStl(5550)
Hindlll(5750)
Clal(5850)
Kpnl(5950)
" __IIfJ~-BamHI(7950)
Clal(8850)
ECORI(8950)
Hindlll(16247)
Xbal(16223)
Kpn 1(14850)
Hindlll(14850)
Clal(14850)
PStl(14450)
BamHI(13959)
Notl(13450)
PStl(13250)
Hindlll(13050)
PStl(12850)
PStl(12450)
PVUI(12250)
Kpnl(11950)
PStl(11050)
Kpn 1(10650)
PVUI(10250)
Notl(10150)
Hindlll(9750)
A.
B.
EcoRI(396)
.~.-Hindlll(500)
Pstl(700)
PStl(1300)
EcoRI(1796)
Hindlll(1847)
Figure 11: Restriction endonuclease maps of the plasmid pXA180 (A)
carrying BAV3 XbaI fragment A and the plasmid pEF73 (B)
carrying the BA V3 EcoRI fragment D. The position of each of the
restriction sites is indicated in base pairs relative to nucleotide 1
of the vector p DC 19.
A.
I
I
I
Kbp 23.1-
9.4 -
6.6 -
M 1 2 3 4 5 6 7 8 9 10
63
B.
Hindlll(16247)
Xbal(16223)
Pstl(16000)
Clal(15600)
Kpnl(15300)
Notl(14700)
Pstl(14500)
EcoRI(14200)
Notl(13900)
Notl(13400)
Notl(12600)
Pstl(11100)
Hindlll(10900)
Clal(10800)
Kpnl(10700)
BamHI(10700)
EcoRI(396)
Xbal(423)
Hindlll(1800)
Kpnl(1800)
Clal(1800)
Pstl(2200)
BamH 1(2700)
Notl(3200)
Pstl(3400)
Hindlll(3600)
Pstl(3800)
Pstl(4200)
PVUI(4500)
Kpnl(4700)
Pstl(5600)
Kpnl(6000)
PVUI(6400)
Notl(6500)
Hindlll(6900)
ECORI(7700)
Clal(7800)
BamHI(8700)
Figure 12. A photograph of a 0.9% agarose gel of plasmid pXA178
digested with HindIII, EcoRI, B amHI, XbaI, P s tl, SalI, Kp nI, ClaI (no
site in pUC19), PvuI (partial) and NotI , lanes 1 to 10, respectively
(A). Lane M is A-HindIII marker. Panel B shows the restriction map
of plasmid pXA 178. The diges tion pattern of pXA 178 amplified in
DH5a (A) shows no sites for ClaI while the restriction map (B)
shows three sites for ClaI. This is due to the fact that these sites
are met h y1ate d and can bede tee ted i n dam / d c m (- v e ) E . co Ii GM48 .
for further analysis. Figure 8 shows a representative Polaroid
photograph of the digestion pattern of the plasmid pEA26.
To aid in deducing the linear order of the cloned EeoRI fragments,
it was necessary to clone other restriction fragments that would overlap
with the EeoRI fragments. XbaI digestion of BAV3 DNA generates four
fragments (A to D) of 15.8, 13.0, 6.0 and 0.4 Kbp in length. The 13.0
and 6.0 Kbp fragments were present at submolar quantities on agarose
gels and, therefore, presumed to be the terminal fragments. This meant
that the 15.8 Kbp fragment was internal and that, by virtue of its size,
would overlap with some of the EeoRI fragments. Therefore, the XbaI
digest of BAV3 DNA was chosen for cloning.
The strategy to clone the BAV3 XbaI fragments was the same as
the one employed to clone the EeoRI fragments (figure 7B). Plasmids
pXA178 (figure 12) and pXA180 (figure I1A) contained the BAV3 XbaI
A fragment in opposite orientation with respect to the polycloning site.
An additional plasmid containing the the BAV3 Xbal D fragment, pXD80,
was generated. Samples of the three plasmids were digested with
BamHI, ClaI, EeoRI, HindIII, KpnI, NotI, NspV, PstI, PvuI, SalI, XbaI and
Xhoi, separated on agarose gel, and photographed for further analysis.
A representative photograph of the XbaI A fragment (pXA178) is shown
in figure 12. The restriction map of the pXD80 is not shown because the
D fragment has no sites for the restriction enzymes used.
3.1.2 Cloning of BAV3 HindIII Fragments:
To further confirm the identity and the linear arrangement of the
E C 0 RI and X ba I cloned fragments and aid in the construction of a
restriction map of the viral genome, the internal BAV3 H i n d I I I
fragments were cloned. Digestion of BAV3 DNA with HindI!! generates
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12 fragments (A to L) ranging in size from 7.8 to 1.3 Kbp. The size
range of the BAV3 Hi ndIII fragments is likely to overlap with the BAV3
EcoRI and XbaI fragments. Cloning of the HindIII fragments was
carried out according to a strategy that was slightly different from those
used for cloning the EcoRI and XbaI fragments (figure 13). The strategy
involved the use of BAV3 DNA partially digested with HindIII. The
digestion of the BAV3 DNA with HindIII to approximately 60% of
completion resulted not only in generation of the full complement of
single BAV3 Hi ndIII fragments, but also some multiple fragments
where the enzyme did not cleave the DNA at the sites between them.
Cloning of such multiple fragments is extremely useful in the
determination of the linear orientation of the HindIII, EcoRI, and XbaI
fragments. The partially digested BAV3 DNA was combined with
HindIII digested pUC19 and ligated with T4 DNA ligase. The ligated
DNA was used to transform competent E. coli strain DH5<X. The
recombinant plasmids isolated from transformed E. coli were digested
with Hi ndIII and separated on agarose gels along with molecular weight
markers and BAV3 DNA digested with HindIII to identify the inserts.
Out of approximately 500 colonies screened, twelve contained
recombinant plasmids carrying single BAV3 HindIII fragments and six
contained recombinant plasmids carrying multiple BAV3 HindIII
fragments as inferred from their co-migration with BAV3 Hi ndI I I
fragments on agarose gels.
Plasmids pHA30 (figure 14), pHB31 (figure 15A), pHC65 (figure
15B), pRe88 (figure 16A), pHD66 (figure 16B), pHD76 (figure 17A),
pRE81 (figure 17B), pHG95 (figure 18B), pHH84 (figure 18C), pHH185
(figure 18A), pHI221 (figure 18D), and pHK177 (figure 19C) contained
BAV3 HindIII fragments A, B, C, C, D, D, E, G, H, H, I, and K respectively.
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Figure 13. Schematic representation showing the cloning strategy
used to clone the BAV3 HindIII fragments and the
recombinant plasmids constructed using this strategy.
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Figure 14. A photograph of a 0.9% agarose gel of plasmid pHA30
dige s ted wi th Hi ndIII, EcoRI, B a mHI, Xbal, P s tl, Sall, Kp nI
ClaI, NotI and NspV, lanes 1 to 10, respectively (A). Lane 1 is
A- Hi ndIII marker. Panel B show s the res triction map of plasmid
pHA30.
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Fig u r e 15: Res triction endonuclease maps of the plasmid pHB 31 (A)
carrying B AV3 Hi ndIII fragment A and the plasmid pHC65 (B)
carrying the BA V3 HindIII fragment C. The position of each of
the restriction sites is indicated in base pairs relative to
nucleotide 1 of the vector pUC19.
A.
B.
Hindlll(4347)
Clal(4250)
Kpnl(4050)
BamHI(4050)
Hindlll(3747)
XhOI(3500)
Notl(3350)
PVUI(3250)
EcoRI(1250)
Clal(1450)
EcoRI(396)
Hindlll(447)
Pstl(650)
XhOI(700)
XhOI(950)
PStl(1050)
PVUI(1350)
Kpnl(1550)
Pstl(2350)
XhOI(2350)
Kpnl(2850)
69
Fig u r e 16: Restriction endonuclease maps of the plasmid pHC88 (A)
carrying BA V3 HindIII fragment C and the plasmid pHD66 (B)
carrying the BA V3 HindIII fragment D. The position of each of
the restriction sites is indicated in base pairs relative to
nucleotide 1 of the vector pUC19.
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Figure 17: Restriction endonuclease maps of the plasmid pHD76 (A)
carrying BAV3 HindIII fragment D and the plasmid pHE81 (B)
carrying the BA V3 HindIII fragment E. The position of each of
the restriction sites is indicated in base pairs relative to
nucleotide 1 of the vector pUC19.
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Fig u r e 18: Restriction endonuclease map s of the plasmids pHH 18 5
(A), pHG95 (B), pHH84 (C) and pHI221 (D) carrying BAV3 HindIII
fragments H, G, H and I respectively. The position of each of the
restriction sites is indicated in base pairs relative to nucleotide 1
of the vector pUC19.
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Plasmids pHC65 and pHC88, pHD66 and pHD76, and pHH185 and pHH84
contained fragments C, D, and H oriented in opposite direction with
respect to the polycloning site of the vector. All of the plasmids
generated were digested with the restriction enzymes stated above,
separated on agarose gels and photographed for restriction enzyme
analysis.
Plasmids pHABCK80 (figure 20A), pHABK72 (figure 20B) and
pHBEK138 (figure 21A) contained fragments A, B, C, E and K cloned
together. This indicated that these fragments may be neighbors in a
linear arrangement. All possible arrangements of these fragments were
analyzed and only one arrangement could account for the three
plasmids. This arrangement is E-B-K-A-C. Plasmid pHCD214 (figure
21B) contained fragments C and D adding fragment D to the core order,
E-B-K-A-C-D. plasmids pHFH224 (figure 19A) and pHGI230 (figure
19B) contained BAV3 HindIII fragments F-H and G-I respectively,
suggesting that these fragments are adjacent and may fall in either side
of the core order. The possibility that these fragments may have been
the result of ligation of single unrelated fragments was always
considered. Although, fragment F was not cloned as a single fragment it
was cloned together with fragment H in plasmid pHFH224. The HindIII
M fragment, reported by Hue and co-workers (1984), was not cloned
nor was it observed on any gel. Fragments Land J were not cloned
either in single or multiple form. These fragments were presumed to be
the end fragments of the viral genome.
3.1.3 Cloning of the BAV3 Bam HI Fragments:
Although twenty six fragments that overlapped to cover
approximately 90% of the viral genome were cloned, none of the
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Fig u r e 19. Restriction endonuclease maps of the plasmids pHFH224
(A), pHGI230 (B), pHK177 (C) carrying BA V3 HindIII fragmen ts
F-H, G-I,and K respectively. The position of each of the restriction
sites is indicated in base pairs relative to nucleotide 1 of the
vector pUC19.
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Figure 20. Restriction endonuclease maps of the plasmid pHABCK80 (A)
carrying BAV3 HindIII fragments A, B, C, and K and the plasmid
pHABK72 (B) carrying the BAV3 HindIII fragments A, B, and K. The
position of each of the restriction sites is indicated in base pairs
relative to nucleotide 1 of the vector pUC19.
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Figure 21. Restriction endonuclease map of the plasmid pHBEK138
(A) carrying BA V3 HindIII fragments E, Band K and the plasmid
pHCD214 (B) carrying BAV3 HindIII fragments C and D. The
position of each of the restriction sites is indicated in base pairs
relative to nucleotide 1 of the vector pUC19.
terminal fragments were cloned in these experiments. To clone the end
fragments it was essential to remove the terminal peptides from the 5'
ends. The terminal peptides were removed by alkaline hydrolysis of
the DNA-peptide complex. Bam HI was chosen for cloning of the end
fragments because the presumed end fragments are large (15.8 and 5.1
Kbp) and, therefore, are easy to locate in the linear arrangement. The
strategy for cloning the BAV3 ends involved removal of the peptides
from BamHI digested BAV3 DNA and cloning the fragments into pUC19
(figure 22). The removal of the peptides leaves a blunt end at the
extreme ends of the genome. Therefore pUC19 was digested with
Bam HI to generate a site compatible with the internal ends of the
terminal fragments and Hi ne II to generate a blunt site compatible with
the external ends of the terminal fragments.
Transformant E. coli colonies were screened for recombinant
plasmids carrying the end fragments using colony hybridization
technique using the HindIII fragments I and E as probes. Plasmids
from ten positive colonies were isolated and analyzed by several
restriction enzymes to identify the inserts. Plasmid pBA59 (figure 23)
was found to contain the Bam HI A end fragment and plasmid pBC40
(figure 24) was found to contain the Bam HI C end fragment. The
restriction enzyme patterns of the plasmids pBA59 and pBC40 are
different from others due to the fact that restriction sites between
Hine!! and BamHI (XbaI, Sail, HineII) were removed from the multiple
cloning site of the vector. The identity of these fragments was further
confirmed by sequencing the pUC19-BAV3 ITR junction (figure 23 and
24). The sequence analysis revealed that the end of the BAV3 DNA
fragment was intact and no nucleotides were removed by the
hydrolysis. Sequencing of the ITR-vector junctions resulted in sequence
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Figure 22. Schematic representation of the cloning strategy used
to clone the internal and terminal B a mHI fragments of BA V3
DNA. B a mHI digested BAV3 DNA was treated with NaOH to
remove the terminal protein and cloned into p DC 19 cut
withBamHI (B), to clone the internal fragments, or pUC19 cut
with B a mHI -HincII (A), to clone the terminal fragments.
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Figure 23. A photograph of a 0.9% agarose gel of plasmid pBA59
di ge s ted wi th Hi ndII I, EcoRI, B a mHI, X b aI, P s tI, SalI, Kp nI, ClaI,
No t1, N s pV an d X hoI, lanes 1 to 11, respeetively (A). Lane M A-
Hi ndI1I marker. Panel B show s the res triction map of pI asmid
pBA59 and the n uleotide sequenee of the p DC 19-B A V3 junction.
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Figure 24. Restriction enzyme map of plasmid pBC40 carrying the
B amHI C terminal fragment and showing the nucleotide
sequence of the pUC19-BAV3 fragment junction. The locations
of restriction sites are shown in base pairs relative to
nucleotide 1 of pUC19.
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Figure 25: Restriction endonuclease maps of the plasmid pBB50 (A)
carrying BAV3 BamHI fragment B and the plasmid pBD34 (B)
carrying the BA V3 B amHI fragment D. The position of each of
the restriction sites is indicated in base pairs relative to the
nucleotide 1 of the vector pUC 19.
8 1
information well into the ITR. Partial sequence of the ITRs (175 bp) is
shown in figure 29.
In addition to cloning of the terminal Bam HI fragments, two
internal fragments were also cloned. This was done to improve the
accuracy of the restriction map and to increase the library of cloned
BAV3 fragments. Plasmids pBB50 (figure 25 A) and pBD34 (figure 25B)
contained BAV3 BamHI fragments Band D respectively.
3.2 Construction of Restriction Maps:
All of the recombinant plasmids isolated from the above
experiments were digested (completely and/or partially) with BamHI,
CiaI, EcoRI, HindIII, KpnI, NotI, NspV, PstI, Pvul, Sail, Xbal and XhoI.
The fragments were separated on agarose gels and their sizes were
estimated by comparison to molecular size markers. Knowing the
locations of the restriction enzyme recognition sites in the vector, it was
possible to locate all the additional sites within the inserts. Where there
was more than one possible location for a given site, all possible
locations were considered. The restriction enzyme maps for all of the
plasmids are shown in the figures indicated above.
In order to construct the restriction maps of the viral DNA, it was
necessary to position the cloned fragments in linear form. This was
accomplished by analysis of the plasmids containing multiple HindIII
fragments. All possible arrangements inferred from these plasmids
were considered. Subsequently, the EcoRI, XbaI and BamHI recognition
sites were located within each of the cloned fragments and trans ~ ated
into the linear maps. Only one of the possible linear arrangements of
the HindIII fragments gave the appropriate EcoRI, XbaI and BamHI size
fragments with two discrepancies. The E C 0 RI B fragment from the
constructed map was 1.4 Kbp longer then the EcoRI B fragment (8.1
Kbp) observed on agarose gels. Also the EcoRI F fragment (1.4 Kbp) was
not accounted for. Analysis of the HindIII digest of pEF73 and the
EcoRI digest of pHG95 and pHHF224 revealed the presence of a HindllI
site at 0.1 Kbp into the E co RI F fragment and no E c 0 RI site in the
H i n dIll F fragment. This indicated the presence of an additional
Hi n dIll fragment (M) of 0.2 Kbp in between the Hi n dIll F and G
fragment. The other discrepancy was that the Xbal D (figure 26)
fragment was not accounted for in any of the plasmids constructed.
Analysis of the recombinant plasmids isolated from methylation
deficient (GM48) E. coli revealed the presence of an additional XbaI site
located between XbaI fragments A and B. The linear arrangement of
the cloned fragments is J-E-B-K-A-C-D-H-F-M-G-I-L for HindIII, G-D-A-
C-B-F-E for EcoRI, B-D-A-C for XbaI and A-E-B-D-C for BamHI (figure
26). This arrangement was further confirmed by the analysis of
partially digested and double digested BAV3 DNA (figure 27).
By overlapping the restriction maps of all the plasmids, it was
possible to rule out most of the incorrect sites within each insert and
confirm their restriction maps. After constructing the above linear
maps, the location of recognition sites for ClaI, Kpnl, Notl, NspV, PstI,
P v u I, Sail and X hoI were translated to yield the restriction map of
BAV3 shown in figure 26. This restriction map was confirmed further
by comparing the restriction fragments that would be generated
according to this map with the actual digestion pattern of BAV3 DNA
(figure 28). All of the restriction maps were correct except for the ClaI
and X ba I maps. Only two sites for C 1a I were found in the cloned
fragments (at 9 and 78.9 mu) whereas the digestion of BAV3 DNA with
CiaI results in six fragments. XbaI D fragment was also missing from
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the constructed map. Upon the restriction enzyme analysis of the
recombinant plasmids isolated from methylation deficient E. coli, an
additional XbaI site and three ClaI sites were located at 35.7, 39.4, 53.5,
and 61.7 mu, respectively.
The size of each restriction fragment was estimated from the
analysis of recombinant plasmids and BAV3 digests (figure 28). The
average sum of these restriction fragments is 35.2 ± 0.2 Kbp which is
consistent with the size of the BAV3 genome reported (table 2).
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Figure 26. Schematic representation of the restriction
enzyme maps of BAV3 DNA. The maps are divided into
100 map units (mu) where each mu is equivalent to
3 5 a bp. Each map show s the restriction enzyme, the
sequence recognized by that enzyme and the location of
the recognition sites on the viral genome. Sites marked
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F i gu r e 27. An autoradiogram of [a 32p]ATP labelled restriction
fragments that result from double digestion of BAV3 DNA with
HindIII-EcoRI (lane 1), HindIII-BamHI (lane 2), HindIII-XbaI
(lane 3), EcoRI-BamHI (lane 4), EcoRI-XbaI (lane 5) andBamHI-
Xb aI (I an e 6). The Iane marked M rep res en t S A- Hind I I I
molecular size marker.
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Figure 28. A photograph of an autoradiogram of [a32 P]ATP labelled
BA V3 restriction fragments separated on 1.1 agarose gel. Lanes 1
to 10 are BAV3 DNA digested with HindIII, EcoRI, BamHI, XbaI,
PstI, SaLI, KpnI, CiaI, PvuI and NotI, respectively. The lanes
marked M repre sen ts the A-Hi ndIII molecular size marker.
Arrows indicate bands that are not apparent in this photograph.
r-
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Table 2. Estimated molecular size (Kbp) of BAV3 restriction fragments generated by:
BamHI Clal EcoRI HindUI Kpnl Notl NspV Pstl Pvul Sail Xbal Xhol
A 18.8 * 10.4 8.7 7.8 7.4 a 10.1 * 15.1 * 5.5 23.0 * 23.5 * 16.0 12.3 *
B 6.0 , 7.5 * 8.1 5.1 7.4 a 8.9 * 10.5 5.5 10.0 * 8.3 * 12.6 * 10.4
C 5.1 * 6.0 6.5 3.9 6.9 * 6.1 9.3 * 3.9 2.0 2.6 6.0 * 7.9 *
D 3.0 5.0 5.5 3.3 4.8 3.8 3.3 0.4 0.5 1.6
E 2.1 3.1 * 3.7 * 2.4 4.5 3.2 3.1 1.5
F 2.9 1.5 2.1 2.9 1.0 2.3 1.2
G 1.2 * 1.9 1.4 0.8 2.0 * 0.2
H 1.8 0.8 1.9
I 1.8 0.5 1.8
J 1.7 * 1.3
K 1.6 1.1
L 1.3 * 1.1
M 0.2 0.9 *
N 0.8
0 0.5
P 0.4
35.1 34.9 35.1 35.0 35.3 35.2 34.9 35.4 35.0 34.8 35.1 35.1
* = Terminal fragments.
a = fragments A and Bare indistinuishable and either can be the terminal fragment.
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A.
CTAG
B.
Core
origin of replication
I
ATTITIGCCA CGTCATTIAT GACGCAACGA CGGCGAGCGT GGCTGCTGAC
GTAACTGTGG GGCGGACGCG TCGCGAGGCG CGGCCGTGGG CGGGGCTGAG
GGCGGCGGGG GCGGCGCGCG GGGCG------3'
Figure 29. A photograph of a sequencing gel (6% Long Ranger)
showing the nucleotide sequence at the j unction of the vector,
pUC19, and the ITR of BAV3 (A). Panel B shows 175 bp nucleotide
sequence of the ITR and the landmarks conserved in
adenoviruses.
Chapter 4: Discussion
The objectives of this study were to clone the BAV3 viral genome
in the form of restriction fragments and construct a detailed restriction
map of the viral genome. The need for such work is, at least, three fold.
First, there are only five restriction enzyme maps available which are
not sufficient and somewhat limiting in designing strategies for
molecular manipulation of the viral DNA. Second, the availability of
well characterized bacterial plasmids carrying viral DNA fragments
allows for an inexpensive and inexhaustible source of the DNA. Third, it
is easier to carry out molecular manipulation on smaller well
characterized fragments rather than on the intact viral genome.
To facilitate the construction of linear restriction enzyme maps
which are a prelude to the molecular manipulation of the viral genome,
the internal BAV3 RE fragments generated by HindIII, EcoRI, BamHI
and Xhal have been cloned into the plasmid vector pUC19. Five of the
seven EcoRI and two of the XbaI fragments were cloned into pUC19.
These fragments represent 86% and 47% of the viral genome,
respectively. All possible locations of BamHI, Clal, EcoRI, HindllI, KpnI,
Notl, NspV, Pstl, Pvul, Sail, Xbal and Xhol sites within each of the
cloned fragments were determined. Although these fragments account
for a large portion of the viral genome, only a partial 'linear
arrangement of the EcoRI fragments was delineated. Thus the need to
clone restriction fragments that would create more overlap was
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apparent. The Hi n dIll internal fragments were good candidates to
overlap with the EcoRI and XbaI cloned fragments.
The cloning of the internal Hi ndIII fragments of the viral genome
resulted in the construction of 18 recombinant plasmids with inserts
representing approximately 90% of the viral genome. Twelve plasmids
containing single BAV3 HlndIII fragment inserts and six plasmids
containing multiple BAV3 Hi ndIII fragment inserts were isolated. The
recognition sites for BamHI, ClaI, EcoRI, HindIII, Kpnl, NotI, NspV, Pstl,
P v u I, Sa II, X b a I and XhoI were all determined within each of the
constructed plasmids. The availability of the plasmids with multiple
fragments, in combination with the analysis of partially digested BAV3
DNA (figure 20), was instrumental in delineating a partial linear
arrangement of the Hi ndIII restriction fragments. By overlapping the
partial Hindlll and EcoRI maps with the restriction enzyme maps of the
HindlII, EcoRI and Xbal cloned fragments, it was possible to delineate
an accurate and more detailed linear map of the internal viral
fragments.
To locate the terminal fragments on the linear map, it was
essential to clone and restriction map the terminal fragments of the
genome. The difficulty with cloning the terminal fragments is the
removal of the residual peptides of the terminal protein without
altering the DNA structure. The phosphodiester bond that links the DNA
and protein is alkaline labile (Desiderio and Kelly, 1981). BAV3 BamHI
restriction fragments were treated with sodium hydroxide to cleave the
DNA-peptide bond, neutralized, annealed, and cloned into pUC19 at the
HincII-BamHI sites. Plasmids containing both the left and right
terminal fragments were obtained. By overlapping the restriction map
of these fragments with the partial linear map of the internal
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fragments, it was possible to construct the complete linear
arrangements of all of the cloned BAV3 restriction fragments. In the
process of cloning the terminal fragments, the two of the internal BAV3
B amHI fragments were also cloned into the B amHI site of pUCI9. The
restriction map of the cloned Bam HI fragments further confirmed the
the location of some restriction maps in the linear map.
The identity of the cloned terminal fragments was confirmed by
nucleotide sequencing of the vector-ITR junction. The determined
nucleotide sequence of this junction (figure 23 and 24) shows that the
blunt 5' end of the genome is ligated to the blunt Hi nell site of the
vector. The presence of a G:C base pair at position one (figure 29),
which is conserved in all Ads (Shinagawa et al., 1987), indicates that
there was no alteration to the viral DNA during the cloning process. The
BAV3 ITR contain the 5'-CATCATC sequence (nucleotides 1-7) typical of
Ads in addition to the highly conserved AATAATCTAC sequence
(nucleotides 8-17). This sequence (1-17) represents the Ad core origin
of replication sequence (Kenny et al., 1988; DePamphilis, 1988).
Furthermore, the highly conserved nucleotides 8 to 17 sequence has
been shown to be protected from nucleases by the initiation of
replication complex, pTP-Ad DNA Polymerase (Kenny et al., 1988). The
ITR sequence also contains the sequence TGGCAGCGGTCCAA which
resembles very closely the NFl binding site (TGG(C or A)NS-7GCCAA) in
other Ads (Kenny et al., 1988; O'Neill and Kelly, 1988; figure 29).
Overall, twenty eight recombinant plasmids carrying internal
BAV3 EcoRI, XbaI, HindIII, and BamHI restriction fragments and two
recombinant plasmids carrying BAV3 Bam HI terminal fragments were
constructed. The plasmids were all mapped with BamHI, ClaI, EcoRI,
HindIII, KpnI, NotI, NspV, PstI, PvuI, Sail, XbaI and XhoI. By virtue of
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overlap, the restriction maps of these plasmids were translated to the
detailed linear BAV3 restriction map shown in figure 26.
The constructed HindIII, EcoRI and BamHI maps are in accordance
with the maps reported by Kurokawa et ale (1978), Hu et ale (1984), and
Zalmanzon et ale (1982). The BAV3 Hindlll M fragment (0.2 Kbp)
reported by Hu et ale (1984a) and Benko et ale (1988) was not detected
on agarose gels in this study nor was it detected by Kurokawa et ale
(1978). This is most likely due to the fact that small fragments tend to
diffuse through the gel which results in the dilution of the DNA to a
point lower than detection limits. In this experiment, the Hi n dIll M
fragment was located on the linear map by overlapping the Hindlll and
the E c 0 RI maps. That is if the M fragment was not there, the E co RI B
fragment would be 1.4 Kbp larger than its actual size and the E co RI F
fragment would not exist. The Hindlll, EcoRI, BamHI, and Xbal maps
were further confirmed by analysis of the digestion pattern of BAV3
DNA simultaneously digested with Hindlll-EcoRI, Hindlll-BamHI,
HindIII-Xbal, EcoRI-BamHI, EcoRI-Xbal and Xbal-BamHI (figure 20).
The fragments generated from these double digests were of the same
size predicted by the restriction maps.
The digestion patterns of BAV3 generated by E co RI and Bam H I
(Figure 22) are similar to the patterns reported by Benko et ale (1988).
The sizes of the RE fragments generated by Hi n dIll, E c 0 RI and Bam H I
(Table 2) were within 0.3 Kbp of those reported by Kurokawa et ale
(1978), Hu et ale (1984a) and Zalmanzon et ale (1982). The average sum
of the restriction fragments generated by the various enzymes was 35.2
± 0.2 Kbp. This is similar to the BAV3 genome size reported by
Kurokawa et ale (1978) and 1.5 Kbp smaller than the size reported by
Benko et ale (1988).
The location of the B amHI sites at 53.9 and 59.8 m.u., the CLaI site
at 53.5 m.ll., the Kp nI site at 53.9 mu and the P stl site at 52.6 mu are
within approximately 0.05 Kbp of the sites reported in the sequence
analysis of the BAV3 hexon gene (Hu et al., 1984a). Furthermore,
sequence analysis of the BAV3 El region carried out in our laboratory
(manuscript in preparation) shows that the location of all restriction
sites between 0 and 11.7% of the genome are within 0.05 Kbp of those
shown in figure 21.
The B amHI site at 59.8 mu seems to be conserved in group C
human Ads (Tooze, 1981) and group I BAVs (Benko and Harrach, 1990).
The 59.8 mu site falls within the BAV3 hexon gene (pll gene) which is
80% homologous to the hexon gene of group CAds (Hu et al., 1984a).
The conservation of this site supports the hybridization studies which
suggest a high degree of evolutionary relatedness between these
viruses. Moreover, this BamHI site is not shared with group II BAVs
supporting the division of the BAVs into the two subgroups.
Benko et ale (1988) reported that PstI digestion of BAV3 DNA
resulted in the generation of fourteen fragments. In this experiment,
fifteen PstI sites were located. This discrepancy could be due to the fact
that most of the Pst I fragments are small and similar in size which
could lead to co-migration of similar fragments that could be mistaken
for a single fragment on an agarose gel.
The BAV3 XbaI map reported by Zalmanzon et ale (1982) shows
two XbaI sites at 33.1 and 84.0 mo. Digestion of BAV3 DNA with XbaI
results in the generation of four fragments (A, B, C, and D; figure 21,
Table 2) which means that there are three XbaI sites In BAV3 genome.
The D fragments was not accounted for in the reported map. Initially,
in this study, only two XbaI sites could be detected in recombinant
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plasmids isolated from DH5a suggesting that the additional sites may be
methylated. Analysis of the recombinant plasmids isolated from the
methylation deficient (dam-jdcm-) E. coli strain GM48 revealed an
additional site for XbaI at 35.7 mu which accounts for the D fragment.
Furthermore, analysis of these plasmids revealed the presence of three
methylated C laI sites at 39.4, 53.5 and 61.7. These C laI sites corrected
the initial discrepancy between the BAV3 DNA C laI digestion pattern
(six fragments) and the ClaI map (only two sites).
In conclusion, the BAV3 genome has been cloned In its entirety In
the form of HindIII, EcoRI, XbaI and BamHI restriction fragments.
These restriction fragments were used to construct a restriction map of
the viral genome with the restriction enzymes Bam HI, C I a I, E coR I ,
HindIII, KpnI, NotI, NspV, PstI, PvuI, SaIl, XbaI and XhoI. The results
obtained in this study are consistent with those reported in the
literature. The restriction maps, presented here, represent the
foundation for further understanding and molecular manipulations of
the BAV3 genome. Furthermore, the restriction enzyme profile of the
BAV3 genome (figure 28) may be used as a quick reference in the
diagnosis of BAV3 infection. Early detection of BAV3 outbreaks would
leading to prevention of epidemics which would be of great economic
benefit.
The ultimate goal of our research group is to engIneer BAV3 based
gene transfer and expression vector(s) analogous to the human Ad
based vectors. Although human Ad have proven to be very effective as
gene transfer and expression vectors in cell culture and various animal
species (Haj-Ahmad and Graham, 1986; Huang et al., 1988; Prevec et al.,
1989; Charlton et al., 1992; Cheng et al., 1992; Jacobs et al., 1992),
immunological memory poses a limitation on the use of these vectors in
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work in our laboratory include sequencing of the El region to allow for
accurate deletions, establishing a cell line that constitutively expresses
the E 1 genes, and reconstitution of the viral genome from cloned
fragments.
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